Search

Your search keyword '"A. García-Layana"' showing total 670 results
Start Over Author "A. García-Layana"
670 results on '"A. García-Layana"'

1. Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice

Author

A. García-Layana, J. García-Arumí, M. S. Figueroa, L. Arias Barquet, J. M. Ruíz-Moreno, L. Monclús-Arbona, and The Spanish AMD Multicenter Group

Subjects
Ophthalmology, RE1-994
Abstract

Purpose. To ascertain wet AMD (wAMD) management patterns in Spain. Methods. A two-round Delphi study conducted through a questionnaire-based survey designed from literature review and validated by an independent Steering Committee. Results. Forty-nine retina specialists experienced in wAMD participated by answering the two-round study questionnaire. Retina specialists are the main responsible for wAMD diagnosis and monitoring, including visits and associated procedures, with a median time per visit of 15 minutes. Standard treatment strategies are based on anti-VEGF administration, including standard loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients). Although treat and extend (T&E) dosing strategy is considered as optimal for wAMD management (78% of the panelists), the main routine healthcare limitations (i.e., visits overload, reduced staff, short visit time, coordination issues, lack of facilities) conduct to self-defined “flexible” strategies, based on T&E and pro-re-nata (PRN) protocols. Conclusion. Proactive treatment patterns (T&E) are the preferred ones by the retina specialists in Spain. However, their proper implementation is difficult due to healthcare resource limitations, as well as organisation and logistic issues. The use of anti-VEGF agents with longer duration of action could facilitate the use of strict T&E approaches according to routine clinical practices.

Published
2019
Full Text
View/download PDF

3. Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021–2030): a societal perspective

Author

Luis Pablo, Gonzaga Garay-Aramburu, Alfredo García Layana, Anxo Fernandez, Inmaculada Vázquez, Xenia Acebes, Jacinto Zulueta, Delfina Balonga, Laura Salinas-Ortega, Álvaro Muñoz, Araceli Casado Gómez, Miguel Ángel Casado, Julia Salvador, Inmaculada Bañón-Rodriguez, and José María Ruíz-Moreno

Subjects
Blindness, Cost, Epidemiology, Visual Impairment, Spain, Medicine (General), R5-920
Abstract

Abstract Objective To estimate the economic impact for the society, generated as a consequence of the onset of loss of vision and irreversible legal blindness, for the main ophthalmologic diseases in Spain: glaucoma, diabetic retinopathy (DR), diabetic macular edema (DME), age-related macular degeneration (AMD) and high myopia (HM). Methods A cost analysis model was developed to estimate the economic burden of glaucoma, DR, DME, AMD and HM over a 10-year time horizon (2021-2030), from a societal perspective in Spain. The epidemiological and economic parameters used in the model were obtained through a literature review. Prevalence, incidence, and progression stages were used to establish the epidemiological flows. Annual costs per patient from publications were included and classified into direct healthcare, direct non-healthcare and indirect costs. Costs from other countries were converted based on purchasing-power-parity (€EUR, PPP). Epidemiological parameters about population and cost results were validated by a panel of experts. All costs were adjusted to euros, 2021 (€, 2021), and using the Consumer Price Index (CPI) of the last 10 years, extrapolated to 2030 euros (€, 2030). Results It was estimated that the total population of patients with the main diseases pathologies (glaucoma, DR, DME, AMD and HM) will increase to 7.99 million patients by 2030, representing an increase of 103%. The total cost by 2030 of all pathologies would amount to 99.8 billion euros. Direct non-healthcare costs account for the largest item (44%), followed by loss of productivity costs (38%), and direct healthcare costs (18%). The pathologies with the highest cumulative costs will be glaucoma (€33.6 billion) and DME (€19.8 billion).The greatest increment costs compared to 2021 will likely be generated by pathologies related to diabetes mellitus, such as DR (703%) and DME (317%). Conclusions Knowing the costs associated with the pathologies that generate loss of vision and irreversible legal blindness is essential to understand the socioeconomic impact associated with these pathologies. Furthermore, the high cost of treating these diseases makes necessary to coordinate efforts between administrations, together with the support of patient associations, to meet their needs.

Published
2024
Full Text
View/download PDF

4. Conjunctival ultraviolet autofluorescence as a biomarker of outdoor time in myopic children

Author

Miriam de la Puente, Valentina Bilbao-Malavé, Jorge González-Zamora, Aura Ortega Claici, Jaione Bezunartea, Leire Gomez-Arteta, Elena Alonso, María Hernández, Patricia Fernández-Robredo, Manuel Sáenz de Viteri, Nerea Martín Calvo, Alfredo García-Layana, Jesús Barrio-Barrio, and Sergio Recalde

Subjects
myopia, light exposure, outdoor activities for children, CUVAF, biomarker, Medicine (General), R5-920
Abstract

IntroductionThe prevalence of myopia has increased significantly in recent years including an earlier onset of myopia development on the pediatric population. The main objective of the study is to compare CUVAF (Conjunctival Ultraviolet Autofluorescence) in children with and without myopia to validate its usefulness as an outdoor protective biomarker.MethodsA case–control observational study was conducted in a child cohort from subjects that attended to the Ophthalmology Department of Clínica Universidad de Navarra for an ophthalmological examination. The general exclusion criteria were (among others): amblyopia, congenital myopia, general ophthalmic disease, and any conjunctival alteration that might difficult the measurement of the CUVAF area. All participants underwent an automatic objective refraction under cycloplegic effect, biometry to measure axial length (AL) and central corneal radius (CCR), and completed a questionnaire about their lifestyle habits. A total of 4 images of the bulbar conjunctiva were taken with blue light in order to quantify the CUVAF area.ResultsA total of 263 subjects (6 to 17 years old) were analyzed with no significant differences in demographic data between case group and control group. There were 50 non-myopic subjects (19%) and 213 myopic subjects (81%). In relation to the outdoor activities (OA), myopic subjects spent significantly fewer hours per week outdoors than the control-group (p = 0.03). About the CUVAF area, the differences between groups were statistically significant, showing that the myopic group has a significantly smaller CUVAF area than the control-group (0.33 ± 0.72 mm2 vs. 0.78 ± 1.22 mm2; p = 0.0023), likewise, the frequency of CUVAF area absence between both groups showed an odds ratio (OR) of 2.52 (CI95% 1.33–4.74). A Pearson correlation test was done, obtaining a strong significant inverse correlation between myopia degree-CUVAF area (r = 0.1877; IC95% 0.068–0.302), and also ratio (AL/CCR)-CUVAF area (p = 0.002 and p = 0.04) respectively.ConclusionCUVAF is a useful biomarker for OA and it has an inverse relationship with myopia degree also in pediatric age, especially after the age of 12, so it could be useful to differentiate the risk of developing myopia. Having a CUVAF area greater than that corresponding to age, protect to myopia 2.5 times, being almost 5 times the protection in case of high myopia.

Published
2024
Full Text
View/download PDF

5. Current Treatment Limitations in Age-Related Macular Degeneration and Future Approaches Based on Cell Therapy and Tissue Engineering

Author

P. Fernández-Robredo, A. Sancho, S. Johnen, S. Recalde, N. Gama, G. Thumann, J. Groll, and A. García-Layana

Subjects
Ophthalmology, RE1-994
Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. With an ageing population, it is anticipated that the number of AMD cases will increase dramatically, making a solution to this debilitating disease an urgent requirement for the socioeconomic future of the European Union and worldwide. The present paper reviews the limitations of the current therapies as well as the socioeconomic impact of the AMD. There is currently no cure available for AMD, and even palliative treatments are rare. Treatment options show several side effects, are of high cost, and only treat the consequence, not the cause of the pathology. For that reason, many options involving cell therapy mainly based on retinal and iris pigment epithelium cells as well as stem cells are being tested. Moreover, tissue engineering strategies to design and manufacture scaffolds to mimic Bruch’s membrane are very diverse and under investigation. Both alternative therapies are aimed to prevent and/or cure AMD and are reviewed herein.

Published
2014
Full Text
View/download PDF

7. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

Author

Abbey, Ashkan, Abdulaeva, Elmira, Abraham, Prema, Adan Civera, Alfredo, Agostini, Hansjurgen, Alezzandrini, Arturo, Alfaro, Virgil, Almony, Arghavan, Altay, Lebriz, Amini, Payam, Antoszyk, Andrew, Aradi, Etelka, Arias, Luis, Arnold, Jennifer, Asaria, Riaz, Astakhov, Sergei, Astakhov, Yury, Awh, Carl C., Balaratnasingam, Chandra, Banerjee, Sanjiv, Baumal, Caroline, Becker, Matthias, Belfort, Rubens, Jr., Bratko, Galina, Bridges, William Z., Jr., Brown, Jamin, Brown, David M., Budzinskaya, Maria, Buffet, Sylvia, Burgess, Stuart, Byon, Iksoo, Cagini, Carlo, Calzada, Jorge, Cameron, Stone, Campochiaro, Peter, Carlson, John, Carneiro, Angela, Chan, Clement, Chang, Emmanuel, Chang, Andrew, Chao, Daniel, Chaudhry, Nauman, Chee, Caroline, Cheek, Andrew, Chen, Shih-Jen, Chen, San-Ni, Cheung, Gemmy, Chexal, Saradha, Chittum, Mark, Chow, David, Cole, Abosede, Connolly, Brian, Cornut, Pierre Loic, Couvillion, Stephen, Danzig, Carl, Daskalov, Vesselin, Dessouki, Amr, Devin, Francois, Dollin, Michael, Dolz, Rosa, Downey, Louise, Dreyer, Richard, Dugel, Pravin, Eichenbaum, David, Eldem, Bora, Engstrom, Robert, Escobar, Joan Josep, Eter, Nicole, Faber, David W., Falk, Naomi, Feiner, Leonard, Vega, Alvaro Fernandez, Ferrone, Philip, Figueroa, Marta, Fine, Howard, Fineman, Mitchell, Fox, Gregory M., Francais, Catherine, Franco, Pablo, Fraser-Bell, Samantha, Fung, Nicholas, Sola, Federico Furno, Gale, Richard, Garcia-Layana, Alfredo, Gasperini, Julie, Gawecki, Maciej, Ghanchi, Faruque, Gill, Manjot, Giunta, Michel, Glaser, David, Goldstein, Michaella, Ulla, Francisco Gomez, Gomi, Fumi, Gonzalez, Victor, Graff, Jordan, Gupta, Sunil, Guthoff, Rainer, Guymer, Robyn, Haas, Anton, Hampton, Robert, Hatz, Katja, Hayashi, Ken, Heier, Jeffrey, Herba, Ewa, Hershberger, Vrinda, Higgins, Patrick, Holekamp, Nancy, Honda, Shigeru, Howard, James, Hu, Allen, Huddleston, Stephen, Iida, Tomohiro, Imaizumi, Hiroko, Ito, Yasuo, Ito, Yasuki, Itty, Sujit, Javey, Golnaz, Javid, Cameron, Kaga, Tatsushi, Kaluzny, Jakub, Kang, Se Woong, Kapoor, Kapil, Karabas, Levent, Kawasaki, Tsutomu, Kelty, Patrick, Kerenyi, Agnes, Khanani, Arshad, Khoramnia, Ramin, Khurana, Rahul, Kimura, Kazuhiro, Klein-Mascia, Kendra, Kobayashi, Namie, Kodjikian, Laurent, Koizumi, Hideki, Kokame, Gregg, Kulikov, Alexey, Kwong, Henry, Kwun, Robert, Lai, Timothy, Lai, Chi-Chun, Lalonde, Laurent, Lanzetta, Paolo, Larsen, Michael, Lavina, Adrian, Lee, Won Ki, Lee, ji Eun, Lee, Seong, Levy, Jaime, Lindsell, Lucas, Liu, Mimi, London, Nikolas, Lotery, Andrew, Lozano Rechy, David, Luckie, Alan, Maberley, David, Maeno, Takatoshi, Mahmood, Sajjad, Makkouk, Fuad, Marcus, Dennis, Margherio, Alan, Masse, Helene, Matsubara, Hisashi, Maturi, Raj, Mehta, Sonia, Menon, Geeta, Mentes, Jale, Michels, Mark, Mitamura, Yoshinori, Mitchell, Paul, Mohamed, Quresh, Mones, Jordi, Lobo, Rodrigo Montemayor, Montero, Javier, Moore, Jeffrey, Mori, Ryusaburo, Morori-Katz, Haia, Mukherjee, Raj, Murata, Toshinori, Muzyka-Wozniak, Maria, Nardi, Marco, Narendran, Niro, Nicolo, Massimo, Nielsen, Jared, Nishimura, Tetsuya, Noda, Kousuke, Nowinska, Anna, Oh, Hideyasu, Ohr, Matthew, Okada, Annabelle, Oleksy, Piotr, Ono, Shinji, Ozdek, Sengul, Ozturk, Banu, Pablo, Luis, Park, Kyu Hyung, Parke, D. Wilk, Parravano, Maria Cristina, Patel, Praveen, Patel, Apurva, Patel, Sunil, Patel, Sugat, Pauleikhoff, Daniel, Pearce, Ian, Pearlman, Joel, Petkova, Iva, Pieramici, Dante, Pozdeyeva, Nadezhda, Qureshi, Jawad, Raczynska, Dorota, Ramirez Estudillo, Juan, Rathod, Rajiv, Razavi, Hessam, Regillo, Carl, Reilly, Gayatri, Ricci, Federico, Rich, Ryan, Romanowska-Dixon, Bożena, Rosenblatt, Irit, Ruiz Moreno, Jose Maria, Sacu, Stefan, Saedon, Habiba, Saeed, Usman, Sagong, Min, Sakamoto, Taiji, Sandhu, Sukhpal, Sararols, Laura, Saravia, Mario, Schadlu, Ramin, Schlottmann, Patricio, Sekiryu, Tetsuju, Seres, András, Sermet, Figen, Shah, Sumit, Shah, Rohan, Shah, Ankur, Sheidow, Thomas, Sheth, Veeral, Shiragami, Chieko, Sikorski, Bartosz, Silva, Rufino, Singerman, Lawrence, Sisk, Robert, Sørensen, Torben L., Souied, Eric, Spinak, David-J., Staurenghi, Giovanni, Steinmetz, Robert, Stoller, Glenn, Stoltz, Robert, Suan, Eric, Suner, Ivan, Yzer, Suzanne, Tadayoni, Ramin, Takahashi, Kanji, Takayama, Kei, Taleb, Alexandre, Talks, James, Terasaki, Hiroko, Thompson, John, Toth-Molnar, Edit, Tran, Khoi, Tuli, Raman, Uchiyama, Eduardo, Vajas, Attila, Lith-Verhoeven, Janneke Van, Varsanyi, Balazs, Viola, Francesco, Virgili, Gianni, Vogt, Gábor, Völker, Michael, Warrow, David, Weber, Pamela, Wells, John A., Wickremasinghe, Sanjeewa, Wieland, Mark, Williams, Geoff, Williams, Thomas, Wong, David, Wong, King, Wong, James, Wong, Ian, Wong, Robert, Wowra, Bogumil, Wykoff, Charles C., Yamashita, Ayana, Yasuda, Kanako, Yilmaz, Gursel, Yiu, Glenn, Yoneda, Ai, Yoon, Young Hee, Yoreh, Barak, Yu, Hyeong Gon, Yu, Seung Young, Yurieva, Tatiana, Zambrano, Alberto, Zatorska, Barbara, Zeolite, Carlos, Khanani, Arshad M., Kotecha, Aachal, Chen, Youxin, Heier, Jeffrey S., Holz, Frank G., Ives, Jane A., Lim, Jennifer I., Lin, Hugh, Michels, Stephan, Quezada Ruiz, Carlos, Schmidt-Erfurth, Ursula, Silverman, David, Singh, Rishi, Swaminathan, Balakumar, and Willis, Jeffrey R.

Published
2024
Full Text
View/download PDF

8. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

Author

Aaberg, Thomas, Jr., Abbey, Ashkan, Abdulaeva, Elmira, Abengoechea, Santiago, Abraham, Prema, Ach, Thomas, Adams, Serrhel, Adan Civera, Alfredo, Adrean, Sean, Agostini, Hansjurgen, Alam, Suhail, Alezzandrini, Arturo, Alfaro, Virgil, Aliseda, Daniel, Almony, Arghavan, Amat, Pedro, Amini, Payam, Antoszyk, Andrew, Arias, Luis, Asaria, Riaz, Avila, Marcos, Awh, Carl C., Bafalluy, Joaquin, Baker, Carl, Bandello, Francesco, Barakat, Mark, Barraza, Karen, Bator, Gyorgy, Baumal, Caroline, Belfort, Rubens, Jr., Bergstrom, Chris, Bertolucci, George, Bochow, Thomas, Bolz, Matthias, Borcz, Emilia, Bordon, Arnaldo, Boyer, David, Bratko, Galina, Brent, Michael, Brown, Jamin, Brown, David M., Budzinskaya, Maria, Buffet, Sylvia, Burgess, Stuart, Burton, Ben, Busquets, Miguel, Cabrera, Francisco, Cagini, Carlo, Calzada, Jorge, Campochiaro, Peter, Carlson, John, Castellarin, Alessandro, Cava, Carlos, Chaikitmongkol, Voraporn, Chan, Clement, Chang, Emmanuel, Chang, Jonathan, Chang, Andrew, Charles, Steve, Chaudhry, Nauman, Chee, Caroline, Chen, Judy, Chen, Fred, Chen, Shih-Jen, Cheong-Leen, Richard, Chiang, Allen, Chittum, Mark, Chow, David, Connolly, Brian, Cornut, Pierre Loic, Csaky, Karl, Danzig, Carl, Das, Arup, Daskalov, Vesselin, Desco, Carmen, Dessouki, Amr, Dickinson, John, Do, Brian, Dollin, Michael, Dugel, Pravin, Dusova, Jaroslava, Eichenbaum, David, Eldem, Bora, Engstrom, Robert, Ernest, Jan, Escobar, Joan Josep, Esposti, Simona, Eter, Nicole, Falk, Naomi, Farkas, Andrej, Feiner, Leonard, Feltgen, Nicolas, Fernandez, Carlos, Fernandez Vega, Alvaro, Ferrone, Philip, Figueira, Joao, Figueroa, Marta, Findl, Oliver, Fine, Howard, Fortun, Jorge, Fox, Gregory M., Foxman, Scott, Framme, Carsten, Fraser-Bell, Samantha, Fu, Arthur, Fukutomi, Akira, Fung, Nicholas, Furno Sola, Federico, Gallego-Pinazo, Roberto, Garcia, Renata, Garcia-Layana, Alfredo, Gawecki, Maciej, George, Sheen, Ghanchi, Faruque, Ghorayeb, Ghassan, Goldberg, Roger, Goldstein, Michaella, Gomes, Nuno, Ulla, Francisco Gomez, Gonzalez, Victor, Greven, Craig, Gupta, Sunil, Guzman, Miguel, Harris, Martin, Hatz, Katja, Hau, Vivienne, Hau, Vincent, Hayashi, Ken, Heier, Jeffrey, Herba, Ewa, Hershberger, Vrinda, Higgins, Patrick, Hirakata, Akito, Ho, Allen, Holekamp, Nancy, Honda, Shigeru, Hsu, Jason, Hu, Allen, Hurcikova, Maria, Ikeda, Yasuhiro, Isernhagen, Ricky, Ito, Yasuki, Jackson, Tim, Jacoby, Rachael, Jafree, Afsar, Javey, Golnaz, Javid, Cameron, Jhaveri, Chirag, Johnson, Mark, Kacerík, Marek, Kaluzny, Jakub, Kampik, Daniel, Kang, Se Woong, Kapoor, Kapil, Karabas, Levent, Kawasaki, Tsutomu, Kerenyi, Agnes, Khanani, Arshad, Khurana, Rahul, Kim, Brian, Kimura, Kazuhiro, Kishino, Genichiro, Kitano, Shigehiko, Klein-Mascia, Kendra, Kokame, Gregg, Korobelnik, Jean Francois, Kulikov, Alexey, Kuriyan, Ajay, Kwong, Henry, Kwun, Robert, Lai, Timothy, Lai, Chi-Chun, Laird, Philip, Lalonde, Laurent, Lanzetta, Paolo, Larsen, Michael, Laugesen, Caroline, Lavinsky, Daniel, Lebreton, Olivier, Lee, Seong, Levy, Jaime, Lipkova, Blandina, Liu, Mimi, Liu, Judy, Lohmann, Chris P., London, Nikolas, Lorenz, Katrin, Lotery, Andrew, Lozano Rechy, David, Lujan, Silvio, Ma, Patrick, Maeno, Takatoshi, Mahmood, Sajjad, Makkouk, Fuad, Malik, Khurram, Marcus, Dennis, Margherio, Alan, Mastropasqua, Leonardo, Maturi, Raj, McCabe, Frank, McKibbin, Martin, Mehta, Hemal, Menon, Geeta, Mentes, Jale, Michalska-Malecka, Katarzyna, Misheva, Aneta, Mitamura, Yoshinori, Mitchell, Paul, Modi, Yasha, Mohamed, Quresh, Montero, Javier, Moore, Jeffrey, Morales Canton, Virgilio, Morori-Katz, Haia, Morugova, Tatiana, Murakami, Tomoaki, Muzyka-Wozniak, Maria, Nardi, Marco, Nemcansky, Jan, Nester-Ostrowska, Kamila, Neto, Julio, Newell, Charles, Nicolo, Massimo, Nielsen, Jared, Noda, Kousuke, Obana, Akira, Ogata, Nahoko, Oh, Hideyasu, Oh, Kean, Ohr, Matthew, Oleksy, Piotr, Oliver, Scott, Olivier, Sebastien, Osher, James, Ozcalışkan, Sehnaz, Ozturk, Banu, Papp, Andras, Park, Kyu Hyung, Parke, D. Wilkin, Parravano, Maria Cristina, Patel, Sugat, Patel, Sunil, Pearce, Ian, Pearlman, Joel, Penha, Fernando, Perente, Irfan, Perkins, Stephen, Pertile, Grazia, Petkova, Iva, Peto, Tunde, Pieramici, Dante, Pollreisz, Andreas, Pongsachareonnont, Pear, Pozdeyeva, Nadezhda, Priglinger, Siegfried, Qureshi, Jawad, Raczynska, Dorota, Rajagopalan, Rajesh, Ramirez Estudillo, Juan, Raskauskas, Paul, Rathod, Rajiv, Razavi, Hessam, Regillo, Carl, Ricci, Federico, Rofagha, Soraya, Romanczak, Dominika, Romanowska-Dixon, Bożena, Rosberger, Daniel, Rosenblatt, Irit, Rosenblatt, Brett, Ross, Adam, Ruamviboonsuk, Paisan, Ruiz Moreno, Jose Maria, Salomão, Gustavo, Sandhu, Sukhpal, Sandner, Dirk, Sararols, Laura, Sawada, Osamu, Schadlu, Ramin, Schlottmann, Patricio, Schuart, Claudia, Seitz, Berthold, Seres, András, Sermet, Figen, Shah, Sandeep, Shah, Ankur, Shah, Rohan, Sharma, Sumit, Sheidow, Thomas, Sheth, Veeral, Shimouchi, Akito, Shimura, Masahiko, Sikorski, Bartosz, Silva, Rufino, Singer, Michael, Singerman, Lawrence, Singh, Rishi, Souied, Eric, Spinak, David J., Spital, Georg, Steinle, Nathan, Stern, Jeffrey, Stoller, Glenn, Stoltz, Robert, Stone, Cameron, Stone, Amy, Suan, Eric, Sugimoto, Masahiko, Sugita, Iichiro, Sun, Jennifer, Sun, Xiaodong, Suner, Ivan, Szalczer, Lajos, Szecsko, Timea, Tabassian, Ali, Tadayoni, Ramin, Takagi, Hitoshi, Takayama, Kei, Taleb, Alexandre, Talks, James, Tan, Gavin, Tanabe, Teruyo, Taylor, Stanford, Thach, Allen, Thompson, John, Tlucek, Paul, Torti, Robert, Tosheva Guneva, Daniela, Toth-Molnar, Edit, Uchiyama, Eduardo, Vajas, Attila, Varma, Deepali, Varsanyi, Balazs, Vassileva, Petja, Vaz-Pereira, Sara, Veith, Miroslav, Vela, Jose Ignacio, Viola, Francesco, Virgili, Gianni, Vogt, Gábor, Vorum, Henrik, Weber, Pamela, Wecke, Thoalf, Wee, Raymond, Weger, Martin, Weishaar, Paul, Wells, John A., Wickremasinghe, Sanjeewa, Williams, Thomas Reginald, Williams, Thomas, Williams, Geoff, Wolf, Armin, Wolfe, Jeremy, Wong, James, Wong, David, Wong, Ian, Wong, Robert, Wowra, Bogumil, Wykoff, Charles C., Wylęgała, Edward, Yang, Chang-Hao, Yasukawa, Tsutomu, Yates, Paul, Yilmaz, Gursel, Yiu, Glenn, Yoon, Young Hee, Yoreh, Barak, Yoshida, Shigeo, Yu, Hyeong Gon, Yu, Seung Young, Yurieva, Tatiana, Zacharias, Leandro, Zaczek Zakrzewska, Karolina, Zambrano, Alberto, Zatorska, Barbara, Zeolite, Carlos, Zheutlin, Jeffrey, Wong, Tien Y., Haskova, Zdenka, Asik, Kemal, Baumal, Caroline R., Csaky, Karl G., Ives, Jane A., Jaffe, Glenn J., Korobelnik, Jean-François, Lin, Hugh, Murata, Toshinori, Schlottmann, Patricio G., Seres, András I., Silverman, David, and Tang, Yannan

Published
2024
Full Text
View/download PDF

10. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Author

Alezzandrini, Arturo, Francone, Anibal Andres, Bafalluy, Joaquín, Bainttein, Silvina, Luna Pinto, Jose, Saravia, Mario, Vidosevich, Matko, Zeolite, Carlos, Furno Sola, Federico, Chang, Andrew, Cornish, Elisa Eleanor Guida, Nguyen, Thanh, Findl, Oliver, Haas, Anton, Kralinger, Martina, Sacu, Stefan, Postelmans, Laurence Dominique, Farah, Michel, Maia, Mauricio, Nehemy, Marcio, Ali, Fareed, Brent, Michael, Dollin, Michael, Gonder, John, Kherani, Amin, Merkur, Andrew, Tuli, Raman, Lopera, Monica Marie, Rodriguez, Francisco, Bradvica, Mario, Ernest, Jan, Kalijurand, Kuldar, Noor, Kai, Cohen, Yves, Creuzot-Garcher, Catherine, De Bats, Flore, Devin, François, Français-Maury, Catherine, Kodjikian, Laurent, Korobelnik, Jean François, Le Mer, Yannick, Quaranta El Maftouhi, Maddalena, Razavi, Sam, Souied, Eric, Tadayoni, Ramin, Weber, Michel, Eter, Nicole, Feltgen, Nicolas, Grisanti, Salvatore, Walter, Peter, Liegl, Raffael, Lorenz, Katrin, Spital, Georg, Priglinger, Siegfried, Spitzer, Martin, Volker, Michael, Krohne, Tim, Jochmann, Claudia, Lohmann, Chris Patrick, Framme, Carsten, Kerenyi, Agnes, Papp, Andras, Seres, Andras, Toth-Molnar, Edit, Tsorbatzoglou, Alexis, Vajas, Atilla, Varsanyi, Balázs, Vogt, Gabor, Bar, Asaf, Eting, Eva, Hauser, David, Levy, Jamie, Mathalone, Nurit, Morori-Katz, Haia, Rosenblatt, Irit, Soudry-Zayit, Shiri, Trivizky, Omert, Bandello, Francesco, Ciardella, Antonio Pasquale, Figus, Michele, Giansanti, Fabrizio, Lanzetta, Paolo, Mariotti, Cesare, Mastropasqua, Leonardo, Midena, Edoardo, Parmeggiani, Francesco, Ricci, Federico, Simonelli, Francesca, Staurenghi, Giovanni, Viola, Francesco, Varano, Monica, Laganovska, Guna, Cisiecki, Sławomir, Jedrzejewski, Wojciech, Kaluzny, Jakub, Misiuk-Hojło, Marta, Abengoechea, Santiago, Iribarren, Javier Araiz, Ascaso, Franciso Javier, Cubero, Juan Manuel, Gallego-Pinazo, Roberto, Gomez-Ulla De Irazazabal, Francisco, Mestre, Ignasi Jürgens, Mones I Carilla, Jordi Manel, Montero Moreno, Javier, María Ruiz Moreno, José, Sararols Ramsay, Laura, Garcia Layana, Alfredo, Downey, Louise, Abraham, Prema, Alfaro, Daniel Virgil, Bagheri, Nika, Barbazetto, Irene, Benevento, Joseph, Bernstein, Paul, Bertolucci, George, Bhavsar, Abdhish, Bridges, William, Brooks, Jr, Harold Logan, Brown, Jamin, Brucker, Alexander, Calvo, Charles M., Capone, Antonio, Carlson, John, Chan, Clement, Chang, Emmanuel, Chan-Kai, Brian, Chaudhry, Nauman, Chen, Sanford, Csaky, Karl, Cummings, Howard, Danzig, Carl, Dessouki, Amr, Dyer, David, Eaton, Alexander, Eichenbaum, David, Faber, David, Feldman, Robert, Finnen, Neil, Freeman, William, Frenkel, Ronald, Gonzales, Christine, Gonzalez, Victor, Gross, John, Gupta, Sunil, Hall, Edward, Han, Min-Kyu, Heier, Jeffrey, Hershberger, Vrinda, Higgins, Patrick, Hsu, Jason, Ip, Michael, Jablon, Eric, Jewart, Brian, John, Vishak, Jonisch, Jonathan, Joondeph, Brian, Kay, Christine, Khanani, Arshad, Kokame, Gregg T., Kwun, Robert, Lai, Michael, Lally, David, Laud, Ketan, Lavina, Adrian, Lee, Michael, Lin, Phoebe, Lin, Haijiang, Manoharan, Niranjan, Marcus, Dennis, Martidis, Adam, McCabe, Frank, Nielsen, Jared, Osher, James, Palmer, James, Patel, Sunil, Pearlman, Joel, Perkins, Stephen, Pirouz, Ashkan, Qureshi, Jawad, Randolph, John, Piri, Niloofar, Rosenfeld, Phillip, Saperstein, David, Scartozzi, Richard, Schwartz, Steven, Sharma, Ashish, Sharma, Atul, Sheth, Veeral, Singer, Michael, Spinak, David, Suan, Eric, Tabandeh, Homayoun, Tabassian, Ali, Uchiyama, Eduardo, Varenhorst, Michael, Wagner, Alan, Warrow, David, Wells, III, John, Wong, Robert, Wong, Keye, Wykoff, Charles, Xavier, Samantha, Ysasaga, Edward, Khanani, Arshad M, Patel, Sunil S, Danzig, Carl J, Eichenbaum, David A, Wykoff, Charles C, Heier, Jeffrey S, Lally, David R, Monés, Jordi, Nielsen, Jared S, Sheth, Veeral S, Kaiser, Peter K, Clark, Julie, Zhu, Liansheng, Patel, Hersh, Tang, Justin, Desai, Dhaval, and Jaffe, Glenn J

Published
2023
Full Text
View/download PDF

11. Could Children’s Myopization Have Been Avoided during the Pandemic Confinement? The Conjunctival Ultraviolet Autofluorescence (CUVAF) Biomarker as an Answer

Author

Miriam de la Puente, Cristina Irigoyen-Bañegil, Aura Ortega Claici, Jorge González-Zamora, Valentina Bilbao-Malavé, Patricia Fernandez-Robredo, María Hernández, Jesús Barrio, Alfredo García-Layana, and Sergio Recalde

Subjects
myopia, CUVAF, confinement, outdoors, COVID-19, Biology (General), QH301-705.5
Abstract

Background: The objective of this study was to evaluate the association of the presence of conjunctival ultraviolet autofluorescence (CUVAF) with the level and progression of myopia and the impact of reduced sunlight exposure during the COVID-19 pandemic confinement (PC). Methods: A retrospective observational study was carried out using three cohorts, children (9–17 years old), young adults (18–25 years old), and adults (>40 years old) with myopia (≤0.75D) and at least three annual eye examinations (before and after PC). All participants underwent an automatic objective refraction and CUVAF area analysis. All the participants filled out a questionnaire regarding lifestyle and myopia history. Results: The 298 recruited participants showed that during the PC, children’s and young adults' myopia progression rate increased on average by −0.50 and −0.30 D/year, respectively, compared with the pre-pandemic level (p < 0.0001 and p < 0.01). A significantly greater progression was observed in those with low baseline myopia compared to those with moderate or high myopia (p < 0.01). CUVAF shows its protective effect associated with outdoor activity (OA) with regard to the age of onset of myopia and mean diopters (p < 0.01). In fact, although there were no differences in the increase in diopters between children with and without CUVAF during the PC, those who had CUVAF started with lower gains (−0.3 D/year) compared to those who did not (−0.5 D/year; p < 0.05). The myopia treatments (atropine drops, Ortho-K, and MiSight® contact lenses) showed a reduction effect in myopic progression rate post-PC in comparison with non-treated children (p < 0.0001, p < 0.0001 and p < 0.01, respectively). Conclusions: The strict restriction of OA during PC led to the rate of myopia progression doubling among children and young adults. This progression occurred mainly in children with previously low myopia, and CUVAF, as a biomarker of OA, reflects its potential to provide benefits in the form of recommended behavioral changes to protect against the development of myopia.

Published
2024
Full Text
View/download PDF

12. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Author

Aaberg, Thomas, Jr, Abbey, Ashkan, Abdulaeva, Elmira, Abengoechea, Santiago, Abraham, Prema, Ach, Thomas, Adams, Serrhel, Adan Civera, Alfredo, Adrean, Sean, Agostini, Hansjurgen, Alam, Suhail, Alezzandrini, Arturo, Alfaro, Virgil, Aliseda, Daniel, Almony, Arghavan, Amat, Pedro, Amini, Payam, Antoszyk, Andrew, Arias, Luis, Asaria, Riaz, Avila, Marcos, Awh, Carl C, Bafalluy, Joaquin, Baker, Carl, Bandello, Francesco, Barakat, Mark, Barraza, Karen, Bator, Gyorgy, Baumal, Caroline, Belfort Jr, Rubens, Bergstrom, Chris, Bertolucci, George, Bochow, Thomas, Bolz, Matthias, Borcz, Emilia, Bordon, Arnaldo, Boyer, David, Bratko, Galina, Brent, Michael, Brown, Jamin, Brown, David M, Budzinskaya, Maria, Buffet, Sylvia, Burgess, Stuart, Burton, Ben, Busquets, Miguel, Cabrera, Francisco, Cagini, Carlo, Calzada, Jorge, Campochiaro, Peter, Carlson, John, Castellarin, Alessandro, Cava, Carlos, Chaikitmongkol, Voraporn, Chan, Clement, Chang, Emmanuel, Chang, Jonathan, Chang, Andrew, Charles, Steve, Chaudhry, Nauman, Chee, Caroline, Chen, Judy, Chen, Fred, Chen, Shih-Jen, Cheong-Leen, Richard, Chiang, Allen, Chittum, Mark, Chow, David, Connolly, Brian, Cornut, Pierre Loic, Csaky, Karl, Danzig, Carl, Das, Arup, Daskalov, Vesselin, Desco, Carmen, Dessouki, Amr, Dickinson, John, Do, Brian, Dollin, Michael, Dugel, Pravin, Dusova, Jaroslava, Eichenbaum, David, Eldem, Bora, Engstrom, Robert, Ernest, Jan, Escobar, Joan Josep, Esposti, Simona, Eter, Nicole, Falk, Naomi, Farkas, Andrej, Feiner, Leonard, Feltgen, Nicolas, Fernandez, Carlos, Fernandez Vega, Alvaro, Ferrone, Philip, Figueira, Joao, Figueroa, Marta, Findl, .Oliver, Fine, Howard, Fortun, Jorge, Fox, Gregory M, Foxman, Scott, Framme, Carsten, Fraser-Bell, Samantha, Fu, Arthur, Fukutomi, Akira, Fung, Nicholas, Furno Sola, Federico, Gallego-Pinazo, Roberto, Garcia, Renata, Garcia-Layana, Alfredo, Gawecki, Maciej, George, Sheen, Ghanchi, Faruque, Ghorayeb, Ghassan, Goldberg, Roger, Goldstein, Michaella, Gomes, Nuno, Gomez Ulla, Francisco, Gonzalez, Victor, Greven, Craig, Gupta, Sunil, Guzman, Miguel, Harris, Martin, Hatz, Katja, Hau, Vivienne, Hau, Vincent, Hayashi, Ken, Heier, Jeffrey, Herba, Ewa, Hershberger, Vrinda, Higgins, Patrick, Hirakata, Akito, Ho, Allen, Holekamp, Nancy, Honda, Shigeru, Hsu, Jason, Hu, Allen, Hurcikova, Maria, Ikeda, Yasuhiro, Isernhagen, Ricky, Ito, Yasuki, Jackson, Tim, Jacoby, Rachael, Jafree, Afsar, Javey, Golnaz, Javid, Cameron, Jhaveri, Chirag, Johnson, Mark, Kacerík, Marek, Kaluzny, Jakub, Kampik, Daniel, Kang, Se Woong, Kapoor, Kapil, Karabas, Levent, Kawasaki, Tsutomu, Kerenyi, Agnes, Khanani, Arshad, Khurana, Rahul, Kim, Brian, Kimura, Kazuhiro, Kishino, Genichiro, Kitano, Shigehiko, Klein-Mascia, Kendra, Kokame, Gregg, Korobelnik, Jean Francois, Kulikov, Alexey, Kuriyan, Ajay, Kwong, Henry, Kwun, Robert, Lai, Timothy, Lai, Chi-Chun, Laird, Philip, Lalonde, Laurent, Lanzetta, Paolo, Larsen, Michael, Laugesen, Caroline, Lavinsky, Daniel, Lebreton, Olivier, Lee, Seong, Levy, Jaime, Lipkova, Blandina, Liu, Mimi, Liu, Judy, Lohmann, Chris P, London, Nikolas, Lorenz, Katrin, Lotery, Andrew, Lozano Rechy, David, Lujan, Silvio, Ma, Patrick, Maeno, Takatoshi, Mahmood, Sajjad, Makkouk, Fuad, Malik, Khurram, Marcus, Dennis, Margherio, Alan, Mastropasqua, Leonardo, Maturi, Raj, McCabe, Frank, McKibbin, Martin, Mehta, Hemal, Menon, Geeta, Mentes, Jale, Michalska-Malecka, Katarzyna, Misheva, Aneta, Mitamura, Yoshinori, Mitchell, Paul, Modi, Yasha, Mohamed, Quresh, Montero, Javier, Moore, Jeffrey, Morales Canton, Virgilio, Morori-Katz, Haia, Morugova, Tatiana, Murakami, Tomoaki, Muzyka-Wozniak, Maria, Nardi, Marco, Nemcansky, Jan, Nester-Ostrowska, Kamila, Neto, Julio, Newell, Charles, Nicolo, Massimo, Nielsen, Jared, Noda, Kousuke, Obana, Akira, Ogata, Nahoko, Oh, Hideyasu, Oh, Kean, Ohr, Matthew, Oleksy, Piotr, Oliver, Scott, Olivier, Sebastien, Osher, James, Ozcalişkan, Sehnaz, Ozturk, Banu, Papp, Andras, Park, Kyu Hyung, Parke, D Wilkin, Parravano, Maria Cristina, Patel, Sugat, Patel, Sunil, Pearce, Ian, Pearlman, Joel, Penha, Fernando, Perente, Irfan, Perkins, Stephen, Pertile, Grazia, Petkova, Iva, Peto, Tunde, Pieramici, Dante, Pollreisz, Andreas, Pongsachareonnont, Pear, Pozdeyeva, Nadezhda, Priglinger, Siegfried, Qureshi, Jawad, Raczynska, Dorota, Rajagopalan, Rajesh, Ramirez Estudillo, Juan, Raskauskas, Paul, Rathod, Rajiv, Razavi, Hessam, Regillo, Carl, Ricci, Federico, Rofagha, Soraya, Romanczak, Dominika, Romanowska-Dixon, Bożena, Rosberger, Daniel, Rosenblatt, Irit, Rosenblatt, Brett, Ross, Adam, Ruamviboonsuk, Paisan, Ruiz Moreno, Jose Maria, Salomão, Gustavo, Sandhu, Sukhpal, Sandner, Dirk, Sararols, Laura, Sawada, Osamu, Schadlu, Ramin, Schlottmann, Patricio, Schuart, Claudia, Seitz, Berthold, Seres, András, Sermet, Figen, Shah, Sandeep, Shah, Ankur, Shah, Rohan, Sharma, Sumit, Sheidow, Thomas, Sheth, Veeral, Shimouchi, Akito, Shimura, Masahiko, Sikorski, Bartosz, Silva, Rufino, Singer, Michael, Singerman, Lawrence, Singh, Rishi, Souied, Eric, Spinak, David J, Spital, Georg, Steinle, Nathan, Stern, Jeffrey, Stoller, Glenn, Stoltz, Robert, Stone, Cameron, Stone, Amy, Suan, Eric, Sugimoto, Masahiko, Sugita, Iichiro, Sun, Jennifer, Sun, Xiaodong, Suner, Ivan, Szalczer, Lajos, Szecsko, Timea, Tabassian, Ali, Tadayoni, Ramin, Takagi, Hitoshi, Takayama, Kei, Taleb, Alexandre, Talks, James, Tan, Gavin, Tanabe, Teruyo, Taylor, Stanford, Thach, Allen, Thompson, John, Tlucek, Paul, Torti, Robert, Tosheva Guneva, Daniela, Toth-Molnar, Edit, Uchiyama, Eduardo, Vajas, Attila, Varma, Deepali, Varsanyi, Balazs, Vassileva, Petja, Vaz-Pereira, Sara, Veith, Miroslav, Vela, Jose Ignacio, Viola, Francesco, Virgili, Gianni, Vogt, Gábor, Vorum, Henrik, Weber, Pamela, Wecke, Thoalf, Wee, Raymond, Weger, Martin, Weishaar, Paul, Wells, John A, Wickremasinghe, Sanjeewa, Williams, Thomas Reginald, Williams, Thomas, Williams, Geoff, Wolf, Armin, Wolfe, Jeremy, Wong, James, Wong, David, Wong, Ian, Wong, Robert, Wowra, Bogumil, Wykoff, Charles C, Wylęgała, Edward, Yang, Chang-Hao, Yasukawa, Tsutomu, Yates, Paul, Yilmaz, Gursel, Yiu, Glenn, Yoon, Young Hee, Yoreh, Barak, Yoshida, Shigeo, Yu, Hyeong Gon, Yu, Seung Young, Yurieva, Tatiana, Zacharias, Leandro, Zaczek Zakrzewska, Karolina, Zambrano, Alberto, Zatorska, Barbara, Zeolite, Carlos, Zheutlin, Jeffrey, Abreu, Francis, Adamis, Anthony P, Basu, Karen, Eichenbaum, David A, Haskova, Zdenka, Lin, Hugh, Loewenstein, Anat, Mohan, Shaun, Pearce, Ian A, Sakamoto, Taiji, Schlottmann, Patricio G, Silverman, David, Sun, Jennifer K, and Willis, Jeffrey R

Published
2022
Full Text
View/download PDF

13. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Author

Abbey, Ashkan, Abdulaeva, Elmira, Abraham, Prema, Adan Civera, Alfredo, Agostini, Hansjurgen, Alezzandrini, Arturo, Alfaro, Virgil, Almony, Arghavan, Altay, Lebriz, Amini, Payam, Antoszyk, Andrew, Aradi, Etelka, Arias, Luis, Arnold, Jennifer, Asaria, Riaz, Astakhov, Sergei, Astakhov, Yury, Awh, Carl C., Balaratnasingam, Chandra, Banerjee, Sanjiv, Baumal, Caroline, Becker, Matthias, Belfort, Rubens, Jr., Bratko, Galina, Bridges, William Jr. Z, Brown, Jamin, Brown, David M., Budzinskaya, Maria, Buffet, Sylvia, Burgess, Stuart, Byon, Iksoo, Cagini, Carlo, Calzada, Jorge, Cameron, Stone, Campochiaro, Peter, Carlson, John, Carneiro, Angela, Chan, Clement, Chang, Emmanuel, Chang, Andrew, Chao, Daniel, Chaudhry, Nauman, Chee, Caroline, Cheek, Andrew, Chen, Shih-Jen, Chen, San-Ni, Cheung, Gemmy, Chexal, Saradha, Chittum, Mark, Chow, David, Cole, Abosede, Connolly, Brian, Cornut, Pierre Loic, Couvillion, Stephen, Danzig, Carl, Daskalov, Vesselin, Dessouki, Amr, Devin, Francois, Dollin, Michael, Dolz, Rosa, Downey, Louise, Dreyer, Richard, Dugel, Pravin, Eichenbaum, David, Eldem, Bora, Engstrom, Robert, Escobar, Joan Josep, Eter, Nicole, Faber, David W., Falk, Naomi, Feiner, Leonard, Fernandez Vega, Alvaro, Ferrone, Philip, Figueroa, Marta, Fine, Howard, Fineman, Mitchell, Fox, Gregory M., Francais, Catherine, Franco, Pablo, Fraser-Bell, Samantha, Fung, Nicholas, Furno Sola, Federico, Gale, Richard, Garcia-Layana, Alfredo, Gasperini, Julie, Gawecki, Maciej, Ghanchi, Faruque, Gill, Manjot, Giunta, Michel, Glaser, David, Goldstein, Michaella, Gomez Ulla, Francisco, Gomi, Fumi, Gonzalez, Victor, Graff, Jordan, Gupta, Sunil, Guthoff, Rainer, Guymer, Robyn, Haas, Anton, Hampton, Robert, Hatz, Katja, Hayashi, Ken, Heier, Jeffrey, Herba, Ewa, Hershberger, Vrinda, Higgins, Patrick, Holekamp, Nancy, Honda, Shigeru, Howard, James, Hu, Allen, Huddleston, Stephen, Iida, Tomohiro, Imaizumi, Hiroko, Ito, Yasuo, Ito, Yasuki, Itty, Sujit, Javey, Golnaz, Javid, Cameron, Kaga, Tatsushi, Kaluzny, Jakub, Kang, Se Woong, Kapoor, Kapil, Karabas, Levent, Kawasaki, Tsutomu, Kelty, Patrick, Kerenyi, Agnes, Khanani, Arshad, Khoramnia, Ramin, Khurana, Rahul, Kimura, Kazuhiro, Klein-Mascia, Kendra, Kobayashi, Namie, Kodjikian, Laurent, Koizumi, Hideki, Kokame, Gregg, Kulikov, Alexey, Kwong, Henry, Kwun, Robert, Lai, Timothy, Lai, Chi-Chun, Lalonde, Laurent, Lanzetta, Paolo, Larsen, Michael, Lavina, Adrian, Lee, Won Ki, Lee, ji Eun, Lee, Seong, Levy, Jaime, Lindsell, Lucas, Liu, Mimi, London, Nikolas, Lotery, Andrew, Lozano Rechy, David, Luckie, Alan, Maberley, David, Maeno, Takatoshi, Mahmood, Sajjad, Makkouk, Fuad, Marcus, Dennis, Margherio, Alan, Masse, Helene, Matsubara, Hisashi, Maturi, Raj, Mehta, Sonia, Menon, Geeta, Mentes, Jale, Michels, Mark, Mitamura, Yoshinori, Mitchell, Paul, Mohamed, Quresh, Mones, Jordi, Montemayor Lobo, Rodrigo, Montero, Javier, Moore, Jeffrey, Mori, Ryusaburo, Morori-Katz, Haia, Mukherjee, Raj, Murata, Toshinori, Muzyka-Wozniak, Maria, Nardi, Marco, Narendran, Niro, Nicolo, Massimo, Nielsen, Jared, Nishimura, Tetsuya, Noda, Kousuke, Nowinska, Anna, Oh, Hideyasu, Ohr, Matthew, Okada, Annabelle, Oleksy, Piotr, Ono, Shinji, Ozdek, Sengul, Ozturk, Banu, Pablo, Luis, Park, Kyu Hyung, Parke, D. Wilki, Parravano, Maria Cristina, Patel, Praveen, Patel, Apurva, Patel, Sunil, Patel, Sugat, Pauleikhoff, Daniel, Pearce, Ian, Pearlman, Joel, Petkova, Iva, Pieramici, Dante, Pozdeyeva, Nadezhda, Qureshi, Jawad, Raczynska, Dorota, Ramirez Estudillo, Juan, Rathod, Rajiv, Razavi, Hessam, Regillo, Carl, Reilly, Gayatri, Ricci, Federico, Rich, Ryan, Romanowska-Dixon, Bożena, Rosenblatt, Irit, Ruiz Moreno, Jose Maria, Sacu, Stefan, Saedon, Habiba, Saeed, Usman, Sagong, Min, Sakamoto, Taiji, Sandhu, Sukhpal, Sararols, Laura, Saravia, Mario, Schadlu, Ramin, Schlottmann, Patricio, Sekiryu, Tetsuju, Seres, András, Sermet, Figen, Shah, Sumit, Shah, Rohan, Shah, Ankur, Sheidow, Thomas, Sheth, Veeral, Shiragami, Chieko, Sikorski, Bartosz, Silva, Rufino, Singerman, Lawrence, Sisk, Robert, Sørensen, Torben L., Souied, Eric, Spinak, David-J, Staurenghi, Giovanni, Steinmetz, Robert, Stoller, Glenn, Stoltz, Robert, Suan, Eric, Suner, Ivan, Suzanne, Yzer, Tadayoni, Ramin, Takahashi, Kanji, Takayama, Kei, Taleb, Alexandre, Talks, James, Terasaki, Hiroko, Thompson, John, Toth-Molnar, Edit, Tran, Khoi, Tuli, Raman, Uchiyama, Eduardo, Vajas, Attila, Van Lith-Verhoeven, Janneke, Varsanyi, Balazs, Viola, Francesco, Virgili, Gianni, Vogt, Gábor, Völker, Michael, Warrow, David, Weber, Pamela, Wells, John A., Wickremasinghe, Sanjeewa, Wieland, Mark, Williams, Geoff, Williams, Thomas, Wong, David, Wong, King, Wong, James, Wong, Ian, Wong, Robert, Wowra, Bogumil, Wykoff, Charles C., Yamashita, Ayana, Yasuda, Kanako, Yilmaz, Gursel, Yiu, Glenn, Yoneda, Ai, Yoon, Young Hee, Yoreh, Barak, Yu, HyeongGon, Yu, Seung Young, Yurieva, Tatiana, Zambrano, Alberto, Zatorska, Barbara, Zeolite, Carlos, Heier, Jeffrey S, Khanani, Arshad M, Quezada Ruiz, Carlos, Basu, Karen, Ferrone, Philip J, Brittain, Christopher, Figueroa, Marta S, Lin, Hugh, Holz, Frank G, Patel, Vaibhavi, Lai, Timothy Y Y, Silverman, David, Swaminathan, Balakumar, Cheung, Chui Ming Gemmy, and Wong, Tien Y

Published
2022
Full Text
View/download PDF

14. Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study

Author

Giocanti-Aurégan A, García-Layana A, Peto T, Gentile B, Chi GC, Mirt M, Kosmas CE, Lambert J, Lanar S, Lewis HB, and Holekamp NM

Subjects
qualitative interviews, treatment experience, adherence, neovascular age-related macular degeneration, diabetic macular edema, Medicine (General), R5-920
Abstract

Audrey Giocanti-Aurégan,1 Alfredo García-Layana,2 Tunde Peto,3 Brittany Gentile,4 Gloria C Chi,4 Mirela Mirt,5 Charlotte E Kosmas,6 Jeremy Lambert,7 Sally Lanar,7 Hannah B Lewis,6 Nancy M Holekamp8 1Ophthalmology Department, Avicenne Hospital, Bobigny, France; 2Clínica Universidad de Navarra, University of Navarra, Pamplona, 31009, Spain; 3Queen’s University Belfast, Belfast, UK; 4Genentech, South San Francisco, CA, USA; 5F. Hoffmann-La Roche, Basel, Switzerland; 6Patient Centred Outcomes, ICON Plc, Reading, UK; 7Patient Centred Outcomes, ICON Plc, Lyon, France; 8Pepose Vision Institute, Chesterfield, MO, USACorrespondence: Audrey Giocanti-Aurégan, Ophthalmology Department, Avicenne hospital, 125 Rue de Stalingrad, Bobigny Cedex, 93009, France, Tel +33 14 895 5815, Fax +33 14 895 5212, Email audrey.giocanti@aphp.frPurpose: Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) patients treated with intravitreally injected anti-vascular endothelial growth factor (anti-VEGF) monotherapies achieve lower vision improvements compared with patients in clinical trials. This qualitative research study aimed to better understand the real-world anti-VEGF treatment experience from nAMD and DME patients’, caregivers’, and retina specialists’ perspectives.Methods: One-time, semi-structured, individual interviews were conducted with adult patients with nAMD or DME treated with anti-VEGF injections for ≥ 12 months, their caregivers, and experienced retina specialists. Interview transcripts were analyzed qualitatively using a thematic analysis approach.Results: A total of 49 nAMD and 46 DME patients, 47 nAMD and 33 DME caregivers, and 62 retina specialists were interviewed in the USA, Canada, France, Germany, Italy and Spain. Most (79%) patients and caregivers reported disruptions to their routine on the day before, the day of, or the day after anti-VEGF injection. Seven nAMD patients (14%) and 14 DME patients (30%) reported having missed an injection visit. The most frequently reported driver for adherence for patients was the doctor–patient relationship (n=66, 70%), whereas for caregivers, it was the ease of booking an appointment (n=25, 32%). Retina specialists reported patient education on the treatment (n=28, 45%) as the most important driver. Treatment barriers could be grouped into four categories: tolerability, clinical factors, logistical parameters and human factors. The most frequently reported barrier to adherence for patients and caregivers was related to side effects (pain/discomfort/irritation: n=63, 67% of patients; n=52, 66% of caregivers), whereas for retina specialists it was logistical parameters (travel logistics: n=44, 71%).Conclusion: This study highlights the importance of the doctor–patient relationship and patient education as key drivers, and treatment tolerability and logistics as key barriers to treatment adherence. Improved doctor–patient relationship/communication and patient education together with new therapies offering convenience, long-acting effectiveness, and better tolerability may improve treatment adherence.Keywords: qualitative interviews, treatment experience, adherence, neovascular age-related macular degeneration, diabetic macular edema

Published
2022

15. Challenges in Diabetic Macular Edema Management: An Expert Consensus Report

Author

Udaondo P, Adan A, Arias-Barquet L, Ascaso FJ, Cabrera-López F, Castro-Navarro V, Donate-López J, García-Layana A, Lavid FJ, Rodríguez-Maqueda M, and Ruiz-Moreno JM

Subjects
diabetes, diabetic macular edema, optical coherence tomography, inflammation, biomarkers, consensus., Ophthalmology, RE1-994
Abstract

Patricia Udaondo,1 Alfredo Adan,2 Luis Arias-Barquet,3 Francisco J Ascaso,4 Francisco Cabrera-López,5 Verónica Castro-Navarro,6 Juan Donate-López,7 Alfredo García-Layana,8 Francisco Javier Lavid,9 Mariano Rodríguez-Maqueda,10 José María Ruiz-Moreno11 1Department of Ophthalmology, Hospital Universitario y Politecnico la FE, Valencia, Spain; 2Department of Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain; 3Department of Ophthalmology, University Complex Bellvitge, Barcelona, Spain; 4Department of Ophthalmology, Hospital Universitario Lozano Blesa, Zaragoza, Spain; 5Department of Ophthalmology, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain; 6Department of Ophthalmology, Hospital General Universitario, Valencia, Spain; 7Department of Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain; 8Department of Ophthalmology, Clínica Universitaria de Navarra, Pamplona, Spain; 9Department of Ophthalmology, Hospital Punta Europa, Algeciras, Cádiz, Spain; 10Department of Ophthalmology, Hospital Virgen del Rocío, Sevilla, Spain; 11Department of Ophthalmology, Hospital Puerta de Hierro, Majadahonda, Madrid, SpainCorrespondence: Patricia UdaondoAiken Prevención y Cirugía ocular, Pizarro, 15 Bajo, Valencia, 46004, SpainTel +34647869228Email draudaondo@gmail.comPurpose: This paper aimed to present daily-practice recommendations for the management of diabetic macular edema (DME) patients based on available scientific evidence and the clinical experience of the consensus panel.Methods: A group of Spanish retina experts agreed to discuss different aspects related with the clinical management of DME patients.Results: Panel was mainly focused on therapeutic objectives in DME management; definition terms; and role of biomarkers as prognostic and predictive factors to intravitreal treatment response. The panel recommends to start DME treatment as soon as possible in those eyes with a visual acuity less than 20/25 (always according to the retina unit capacity). Naïve patient was defined, in a strict manner, as a patient who, up to that moment, had never received any treatment. A refractory DME patient may be defined as the one who did not achieve a complete resolution of the disease, regardless of the treatment administered. Different optical coherence tomography biomarkers, such as disorganization of the retinal inner layers, hyperreflective dots, and cysts, have been identified as prognostic factors.Conclusion: This document has sought to lay down a set of recommendations and to identify key issues that may be useful for the daily management of DME patients.Keywords: diabetes, diabetic macular edema, optical coherence tomography, inflammation, biomarkers, consensus

Published
2021

16. Matrix Metalloproteinase 13 Is Associated with Age-Related Choroidal Neovascularization

Author

Jorge González-Zamora, María Hernandez, Sergio Recalde, Jaione Bezunartea, Ana Montoliu, Valentina Bilbao-Malavé, Sara Llorente-González, Alfredo García-Layana, and Patricia Fernández-Robredo

Subjects
matrix metalloproteinase, age-related macular degeneration, oxidative stress, choroidal neovascularization, angiogenesis, Therapeutics. Pharmacology, RM1-950
Abstract

Age-related macular degeneration (AMD) is a leading cause of severe vision loss in older individuals in developed countries. Despite advances in our understanding of AMD, its pathophysiology remains poorly understood. Matrix metalloproteinases (MMPs) have been proposed to play a role in AMD development. In this study, we aimed to characterize MMP-13 in AMD. We used retinal pigment epithelial cells, a murine model of laser-induced choroidal neovascularization, and plasma samples from patients with neovascular AMD to conduct our study. Our results show that MMP13 expression significantly increased under oxidative stress conditions in cultured retinal pigment epithelial cells. In the murine model, MMP13 was overexpressed in both retinal pigment epithelial cells and endothelial cells during choroidal neovascularization. Additionally, the total MMP13 levels in the plasma of patients with neovascular AMD were significantly lower than those in the control group. This suggests a reduced diffusion from the tissues or release from circulating cells in the bloodstream, given that the number and function of monocytes have been reported to be deficient in patients with AMD. Although more studies are needed to elucidate the role of MMP13 in AMD, it could be a promising therapeutic target for treating AMD.

Published
2023
Full Text
View/download PDF

17. Suitability of machine learning for atrophy and fibrosis development in neovascular age‐related macular degeneration.

Author

de la Fuente, Jesus, Llorente‐González, Sara, Fernandez‐Robredo, Patricia, Hernandez, María, García‐Layana, Alfredo, Ochoa, Idoia, Recalde, Sergio, Alonso‐Iglesias, Elena, Salinas‐Alamán, Ángel, Bezunartea‐Bezunartea, Jaione, Abraldes López‐Veiga, Maximino J., Díez‐Sotelo, Marta, Sarandeses‐Díez, María Teresa, Taboada‐Gago, María Dolores, Asorey, María Knight, Valverde‐Megías, Alicia, Felipe‐Márquez, Gema, Honrubia‐Grijalbo, Ana, Núñez‐Benito, María Esther, and Escobar‐Barranco, José J.

Subjects
MACULAR degeneration, MACHINE learning, ATROPHY, FIBROSIS, DIABETIC retinopathy
Abstract

Purpose: To assess the suitability of machine learning (ML) techniques in predicting the development of fibrosis and atrophy in patients with neovascular age‐related macular degeneration (nAMD), receiving anti‐VEGF treatment over a 36‐month period. Methods: An extensive analysis was conducted on the use of ML to predict fibrosis and atrophy development on nAMD patients at 36 months from start of anti‐VEGF treatment, using only data from the first 12 months. We use data collected according to real‐world practice, which includes clinical and genetic factors. Results: The ML analysis consistently identified ETDRS as a relevant factor for predicting the development of atrophy and fibrosis, confirming previous statistical analyses. Also, it was shown that genetic variables did not demonstrate statistical relevance in the prediction. Despite the complexity of predicting macular degeneration, our model was able to obtain a balance accuracy of 63% and an AUC of 0.72 when predicting the development of atrophy or fibrosis at 36 months. Conclusion: This study demonstrates the potential of ML techniques in predicting the development of fibrosis and atrophy in nAMD patients receiving long‐term anti‐VEGF treatment. The findings highlight the importance of clinical factors, particularly ETDRS (early treatment diabetic retinopathy study) visual acuity test, in predicting these outcomes. The lessons learned from this research can guide future ML‐based prediction tasks in the field of ophthalmology and contribute to the design of data collection processes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid

Author

Rosa M. Coco-Martin, Cristina Andrés-Iglesias, Girish K. Srivastava, Javier Lagos-Rodriguez, Miguel Ruiz-Tevah, Mario R. Díaz-Cárdenas, Ivan Fernandez-Bueno, Juan García-Serna, María T. García-Gutierrez, Alfredo García-Layana, and J. Carlos Pastor

Subjects
Medicine, Science
Abstract

Abstract Serious intraocular toxicity cases have been reported worldwide after the use of different perfluorocarbon liquids. The current study reports for the first-time the clinical pictures of cases of acute intraocular toxicity caused by MEROCTANE, a perfluoro-octane commercialized by a Turkish company and distributed in many countries. A series of 18 cases from Chile and Spain was retrospectively analysed. To evaluate the impurity profile, a suspicious MEROCTANE sample (lot OCT.01.2013) was analysed by gas chromatography mass spectrometry and compared with a non-suspicious sample of the same commercial perfluoro-octane (lot OCT 722011). Cytotoxicity was tested following a direct-contact method, taking into consideration the high volatility and hydrophobicity of perfluoro-octane and following the ISO 10993 guideline. Cytotoxicity test showed clear cytotoxic effects of the analysed batch (less than 9% of cell viability). Moreover, chemical analysis demonstrated the presence of many contaminants, some highly toxic (acids and alcohols). Perfluorocarbon liquids are useful tools for intraocular surgery but companies and Agencies of Medical Devices must implement measures that guarantee the safety of these products based on both chemical and cytotoxicity analysis for every batch. Medical staff should be encouraged to report any suspected case to their respective National Agencies.

Published
2021
Full Text
View/download PDF

19. Could Children’s Myopization Have Been Avoided during the Pandemic Confinement? The Conjunctival Ultraviolet Autofluorescence (CUVAF) Biomarker as an Answer

Author

de la Puente, Miriam, primary, Irigoyen-Bañegil, Cristina, additional, Ortega Claici, Aura, additional, González-Zamora, Jorge, additional, Bilbao-Malavé, Valentina, additional, Fernandez-Robredo, Patricia, additional, Hernández, María, additional, Barrio, Jesús, additional, García-Layana, Alfredo, additional, and Recalde, Sergio, additional

Published
2024
Full Text
View/download PDF

20. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

Author

de Andrés-Nogales, Fernando, Casado, Miguel Ángel, Trillo, José Luis, Ruiz-Moreno, José María, Martínez-Sesmero, José Manuel, Peralta, Gemma, Poveda, José Luis, Ortiz, Pere, Ignacio, Emilio, Zarranz-Ventura, Javier, Udaondo, Patricia, Mur, Carlos, Álvarez, Eloísa, Cervera, Enrique, Martínez, Mercedes, Llorente, Iñaki, Zulueta, Jacinto, Rodríguez-Maqueda, Mariano, García-Layana, Alfredo, and Martínez-Olmos, José

Published
2020
Full Text
View/download PDF

22. Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization

Author

Hernandez, Maria, Recalde, Sergio, Garcia-Garcia, Laura, Bezunartea, Jaione, Miskey, Csaba, Johnen, Sandra, Diarra, Sabine, Sebe, Attila, Rodriguez-Madoz, Juan Roberto, Pouillot, Severine, Marie, Corinne, Izsvák, Zsuzsanna, Scherman, Daniel, Kropp, Martina, Prosper, Felipe, Thumann, Gabriele, Ivics, Zoltán, Garcia-Layana, Alfredo, and Fernandez-Robredo, Patricia

Published
2019
Full Text
View/download PDF

24. Clinical Characterization of Inpatients with Acute Conjunctivitis: A Retrospective Analysis by Natural Language Processing and Machine Learning

Author

Nuria Valdés Sanz, Alfredo García-Layana, Teresa Colas, Manuel Moriche, Manuel Montero Moreno, and Giorgio Ciprandi

Subjects
acute conjunctivitis, bacterial infection, in-hospital patients, natural language processing, machine learning, electronic medical reports, Technology, Engineering (General). Civil engineering (General), TA1-2040, Biology (General), QH301-705.5, Physics, QC1-999, Chemistry, QD1-999
Abstract

Background Acute bacterial conjunctivitis (ABC) is a relatively common medical condition caused by different pathogens. Although it rarely threatens vision, it is one of the most common conditions that cause red eyes and may be accompanied by discomfort and discharge. The study aimed to identify and characterize inpatients with ABC treated with topical antibiotics. Methods The EHRead® technology, based on natural language processing (NLP) and machine learning, was used to extract and analyze the clinical information in the electronic health records (EHRs) of antibiotic-treated patients with conjunctivitis and admitted to five hospitals in Spain between January 2014 and December 2018. Categorical variables were described by frequency, whereas numerical variables included the mean, standard deviation, median, and quartiles. Results From a source population of 2,071,812 adult patients who attended the participating hospitals in the study period, 11,110 patients diagnosed with acute conjunctivitis were identified. Six thousand five hundred eighty-three patients were treated with antibiotics, comprising the final study population. Microbiology was tested only on 12.1% of patients. Antibiotics, mainly tobramycin, and corticosteroids, mainly dexamethasone, were usually prescribed. NSAIDs were also used in about 50% of patients, always combined with antibiotics. Conclusions The present study provided a realistic representation of the hospital practice concerning managing patients with acute antibiotic-treated conjunctivitis. The diagnosis is usually based on the clinical ground, microbiology is rarely tested, few bacteria species are involved, and local antibiotics are frequently associated with corticosteroids and/or NSAIDs. Moreover, this study provided clinically relevant outcomes, based on new technology, that could be applied in clinical practice.

Published
2022
Full Text
View/download PDF

26. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

Author

Izquierdo-Serra, Jordi, primary, Martin-Pinardel, Ruben, additional, Moll-Udina, Aina, additional, Bernal-Morales, Carolina, additional, Garay-Aramburu, Gonzaga, additional, Sanchez-Monroy, Jorge, additional, Arruabarrena, Carolina, additional, Fernandez-Hortelano, Ana, additional, Figueroa, Marta S., additional, Abraldes, Maximino, additional, Lavid de los Mozos, Francisco Javier, additional, Zapata, Miguel Angel, additional, Ruiz-Moreno, Jose Maria, additional, Broc-Iturralde, Laura, additional, Gonzalez-Guijarro, Jacobo, additional, Escobar-Barranco, Jose Juan, additional, Gallego-Pinazo, Roberto, additional, Parrado-Carrillo, Alba, additional, Dotti-Boada, Marina, additional, Alforja, Socorro, additional, Figueras-Roca, Marc, additional, Barthelmes, Daniel, additional, Gillies, Mark C., additional, Casaroli-Marano, Ricardo P., additional, Zarranz-Ventura, Javier, additional, Izquierdo-Serra, Jordi, additional, Serrano, Alba, additional, Grau, Jose, additional, Sararols-Ramsay, Laura, additional, Londoño, Gabriel, additional, Olivera, Maximiliano, additional, Bañon, Karim, additional, Rethati, Cynthia, additional, Calvo, Pilar, additional, Sánchez, Jorge, additional, Puzo, Martín, additional, Ruiz-Moreno, Oscar, additional, Larrauri-Arana, Arantza, additional, Gómez-Moreno, Angela, additional, Rodríguez-Feijoo, David, additional, Diaz-de-Durana-Santa-Coloma, Enrique, additional, Aldazabal-Echeveste, Maialen, additional, del-Barrio-Lopez-de-Ipiña, Zuriñe, additional, Herrero-Díaz, Irene, additional, García-Arumí, José, additional, Brosa, Helena, additional, Sánchez-Vela, Laura, additional, Montejano-Milner, Rafael, additional, de Aragón, Fernando, additional, Abraldes López-Veiga, Maximino José, additional, Gómez Conde, María Lidia, additional, Rodríguez-Cid, María José, additional, Fernández Rodríguez, María Isabel, additional, Almuiña Varela, Pablo, additional, Fernández-Hortelano, Ana, additional, Zarallo-Gallardo, Jesús, additional, Cobo-Soriano, Rosario, additional, Lozano-Escobar, Inmaculada, additional, Moreno-Martín, Paula, additional, Ruiz-Moreno, Jose M., additional, Vega-González, Rocío, additional, García Zamora, María, additional, Flores-Moreno, Ignacio, additional, Valldeperas, Xavier, additional, Mira, Ferran Vilaplana, additional, Sánchez, Sandra Gómez, additional, Figueroa, Pamela Campos, additional, Fernandez-Bonet, Manel, additional, Pina-Marín, Begoña, additional, Martínez, Eva Salinas, additional, González Guijarro, Jacobo, additional, Acebes García, Muxima, additional, Sanchís, Sonia Aparicio, additional, Fernández, Jonathan Cacelliere, additional, Belmonte Grau, Marta, additional, Ascaso Puyuelo, Francisco Javier, additional, Honrubia Grijalbo, Ana, additional, Boned Murillo, Ana, additional, Díaz Barreda, María Dolores, additional, Rivasés, Guillermo Pérez, additional, El Bakkali, Ismael Bakkali, additional, Cholbi, Marta, additional, Dolz-Marco, Rosa, additional, Ciancas, Esther, additional, Gonzalez-López, Julio José, additional, Haskour, Cesar Azrak, additional, Sánchez, Alvaro Piñero, additional, Muñoz Sanz, Nélida, additional, Carreño, Ester, additional, Ventura, Nestor, additional, Carnota-Méndez, Pablo, additional, Méndez-Vázquez, Carlos, additional, Torres-Borrego, Carlos, additional, Velázquez-Villoria, Daniel, additional, García-Layana, Alfredo, additional, Saenz de Viteri, Manuel, additional, Alonso, Elena, additional, Castillón Torre, Luis J., additional, Muñoz, Pablo Catalán, additional, Sempere, María Eugenia Tena, additional, Álvarez Gil, María de Fátima, additional, Piñas García, Purificación, additional, Mantrana Bermejo, María Eugenia, additional, de los Mozos, Francisco Javier Lavid, additional, Asencio Duran, Mónica, additional, Arias-Barquet, Lluis, additional, Cobos Martín, Estefanía, additional, Parra, Daniel Lorenzo, additional, Rodríguez-Núñez, Marta, additional, Gesto, Ana Campo, additional, Pareja Esteban, Jesús, additional, Ruiz del Tiempo, María del Pilar, additional, Rodríguez-Maqueda, Mariano, additional, Espiñeira Periñan, María Angeles, additional, and Sotomayor Toribio, Magdalena, additional

Published
2023
Full Text
View/download PDF

27. Legume consumption is inversely associated with type 2 diabetes incidence in adults: A prospective assessment from the PREDIMED study

Author

Serra-Mir, M., Pérez-Heras, A., Viñas, C., Casas, R., Medina-Renom, A., Baena, J.M., García, M., Oller, M., Amat, J., Duaso, I., García, Y., Iglesias, C., Simón, C., Quinzavos, L., Parra, L., Liroz, M., Benavent, J., Clos, J., Pla, I., Amorós, M., Bonet, M.T., Martín, M.T., Sánchez, M.S., Altirriba, J., Manzano, E., Altés, A., Cofán, M., Valls-Pedret, C., Sala-Vila, A., Doménech, M., Bulló, M., Babio, N., Basora, J., González, R., Molina, C., Márquez, F., Martínez, P., Ibarrola, N., Sorlí, M., García Roselló, J., Castro, A., Martin, F., Tort, N., Isach, A., Guasch-Ferre, M., Cabré, J.J., Mestres, G., Paris, F., Llauradó, M., Pedret, R., Basells, J., Vizcaino, J., Segarra, R., Frigola, J., Costa-Vizcaino, J., Salas-Huetos, A., Boj, J., Montañes, D., Papandreou, Christopher, Fernández-Ballart, J., Carrasco, P., Ortega-Azorín, C., Asensio, E.M., Osma, R., Barragán, R., Francés, F., Guillén, M., González, J.I., Sáiz, C., Portolés, O., Giménez, F.J., Coltell, O., Fernández-Carrión, R., Guillem-Sáiz, P., González-Monje, I., Quiles, L., Pascual, V., Riera, C., Pages, M.A., Godoy, D., Carratalá-Calvo, A., Sánchez-Navarro, S., Valero-Barceló, C., Tello, S., Vila, J., de la Torre, R., Muñoz-Aguayo, D., Elosua, R., Marrugat, J., Schröder, H., Molina, N., Maestre, E., Rovira, A., Castañer, O., Farré, M., Toledo, E., Ruiz-Canela, M., Sanjulián, B., Sánchez-Tainta, A., Eguaras, S., Martí, A., Buil-Cosiales, P., SerranoMartínez, M., Diez-Espino, J., García-Arellano, A., Martínez-Lapiscina, E.H., Goñi, E., Vázquez, Z., Berrade, N., Extremera-Urabayen, V., Arroyo-Azpa, C., García-Pérez, L., Villanueva-Telleria, J., Cortés-Ugalde, F., Sagredo-Arce, T., Vigata-López, M.D., Arceiz Campo, M.T., Urtasun-Samper, A., Gueto Rubio, M.V., Churio-Beraza, B., Arós, F., Salaverria, I., del Hierro, T., Algorta, J., Francisco, S., Alonso-Gómez, A., Sanz, E., Rekondo, J., Belló, M.C., Loma-Osorio, A., Gómez-Gracia, E., Wärnberg, J., Benítez Pont, R., Bianchi Alba, M., Gómez-Huelgas, R., Martínez-González, J., Velasco García, V., de Diego Salas, J., Baca Osorio, A., Gil Zarzosa, J., Sánchez Luque, J.J., Vargas López, E., Ruiz-Gutiérrez, V., Sánchez Perona, J., Montero Romero, E., García-García, M., Jurado-Ruiz, E., Fiol, M., Romaguera, D., García-Valdueza, M., Moñino, M., Munuera, S., Vivó, M., Bestard, F., Munar, J.A., Coll, L., Proenza, A., Prieto, R., Frontera, G., Fiol, F., Ginard, M., Jover, A., García, J., Santos-Lozano, J.M., Ortega-Calvo, M., Mellado, L., García-Corte, F.J., Román, P., Iglesias, P., Corchado, Y., Miró-Moriano, L., Domínguez-Espinaco, C., Lozano-Rodriguez, J.M., Vaquero-Diaz, S., López- Sabater, M.C., Castellote-Bargalló, A.I., Quifer-Rada, P., Tresserra-Rimbau, A., Álvarez-Pérez, J., Díaz-Benítez, E.M., Sánchez-Villegas, A., Casañas-Quintana, L.T., Pérez-Cabrera, J., Ruano-Rodríguez, C., Bautista-Castaño, I., Sarmiento de la Fe, F., García Pastor, J.A., Díaz-González, B.V., Castillo Anzalas, J.M., Sosa-Also, R.E., Medina-Ponce, J., de la Cruz, E., Fanlo-Maresma, M., Galera, A., Trias, F., Sarasa, I., Corbella, E., Corbella, X., Cabezas, C., Vinyoles, E., Rovira, M.A., García, L., Flores, G., Verdú, J.M., Baby, P., Ramos, A., Mengual, L., Roura, P., Yuste, M.C., Guarner, A., Santamaría, M.I., Mata, M., de Juan, C., Brau, A., Tur, J.A., Portillo, M.P., Sáez, G., Aldamiz-Echevarría, M., Alonso-Gómez, A.M., Berjón, J., Forga, L., Gállego, J., García-Layana, A., Larrauri, A., Portu-Zapirain, J., Timiraus-Fernández, J., Becerra-Tomás, Nerea, Díaz-López, Andrés, Rosique-Esteban, Núria, Ros, Emilio, Buil-Cosiales, Pilar, Corella, Dolores, Estruch, Ramon, Fitó, Montserrat, Serra-Majem, Lluís, Arós, Fernando, Lamuela-Raventós, Rosa Maria, Fiol, Miquel, Santos-Lozano, José Manuel, Díez-Espino, Javier, Portoles, Olga, and Salas-Salvadó, Jordi

Published
2018
Full Text
View/download PDF

28. Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation

Author

Jorge González-Zamora, María Hernandez, Sergio Recalde, Jaione Bezunartea, Ana Montoliu, Valentina Bilbao-Malavé, Josune Orbe, José A. Rodríguez, Sara Llorente-González, Patricia Fernández-Robredo, and Alfredo García-Layana

Subjects
matrix metalloproteinase, age-related macular degeneration, oxidative stress, choroidal neovascularisation, angiogenesis, Biology (General), QH301-705.5
Abstract

Age-related macular degeneration (AMD) is currently the main cause of severe visual loss among older adults in developed countries. The pathophysiology has not been clarified, but oxidative stress is believed to play a major role. Matrix metalloproteinases (MMP) may play a prominent role in several steps of the pathophysiology of AMD, especially in its neovascular form; therefore, there is of great interest in understanding their role in choroidal neovascularisation. This study aimed to elucidate the role of MMP10 in the development of choroidal neovascularisation (CNV). We have demonstrated that MMP10 was expressed by retinal pigment epithelium cells and endothelial cells of the neovascular membrane, in cell culture, mouse and human retina. MMP10 expression and activity increased under oxidative stress conditions in ARPE-19 cells. MMP10-/- mice developed smaller laser-induced areas of CNV. Furthermore, to exclude a systemic MMP10 imbalance in these patients, plasma MMP10 concentrations were assessed in an age- and sex-matched sample of 52 control patients and 52 patients with neovascular AMD and no significant differences were found between the groups, demonstrating that MMP10 induction is a local phenomenon. Our findings suggest that MMP10 participates in the development of choroidal neovascularisation and promotes MMP10 as a possible new therapeutic target.

Published
2022
Full Text
View/download PDF

29. Dairy products intake and the risk of incident cataracts surgery in an elderly Mediterranean population: results from the PREDIMED study

Author

Camacho-Barcia, Lucía, Bulló, Mònica, García-Gavilán, Jesús F., Martínez-González, Miguel A., Corella, Dolores, Estruch, Ramón, Fitó, Montse, Gómez-Gracia, Enrique, Arós, Fernando, Fiol, Miquel, Santos-Lozano, José M., Serra-Majem, Lluís, Pintó, Xavier, Basora, Josep, Toledo, Estefanía, Muñoz, Miguel A., Zanon-Moreno, Vicente, García-Layana, Alfredo, and Salas-Salvadó, Jordi

Published
2019
Full Text
View/download PDF

30. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

Author

Izquierdo-Serra, Jordi, Martin-Pinardel, Ruben, Moll-Udina, Aina, Bernal-Morales, Carolina, Garay-Aramburu, Gonzaga, Sanchez-Monroy, Jorge, Arruabarrena, Carolina, Fernandez-Hortelano, Ana, Figueroa, Marta S., Abraldes, Maximino, Lavid de los Mozos, Francisco Javier, Zapata, Miguel Angel, Ruiz-Moreno, Jose Maria, Broc-Iturralde, Laura, Gonzalez-Guijarro, Jacobo, Escobar-Barranco, Jose Juan, Gallego-Pinazo, Roberto, Parrado-Carrillo, Alba, Dotti-Boada, Marina, Alforja, Socorro, Figueras-Roca, Marc, Barthelmes, Daniel, Gillies, Mark C., Casaroli-Marano, Ricardo P., Zarranz-Ventura, Javier, Zarranz-Ventura, Javier, Parrado-Carrillo, Alba, Figueras-Roca, Marc, Moll-Udina, Aina, Izquierdo-Serra, Jordi, Serrano, Alba, Grau, Jose, Bernal-Morales, Carolina, Alforja, Socorro, Casaroli-Marano, Ricardo P., Sararols-Ramsay, Laura, Londoño, Gabriel, Olivera, Maximiliano, Bañon, Karim, Rethati, Cynthia, Calvo, Pilar, Sánchez, Jorge, Puzo, Martín, Ruiz-Moreno, Oscar, Garay-Aramburu, Gonzaga, Larrauri-Arana, Arantza, Gómez-Moreno, Angela, Rodríguez-Feijoo, David, Diaz-de-Durana-Santa-Coloma, Enrique, Aldazabal-Echeveste, Maialen, del-Barrio-Lopez-de-Ipiña, Zuriñe, Herrero-Díaz, Irene, García-Arumí, José, Brosa, Helena, Sánchez-Vela, Laura, Zapata, Miguel Angel, Arruabarrena, Carolina, Montejano-Milner, Rafael, de Aragón, Fernando, Abraldes López-Veiga, Maximino José, Gómez Conde, María Lidia, Rodríguez-Cid, María José, Fernández Rodríguez, María Isabel, Almuiña Varela, Pablo, Fernández-Hortelano, Ana, Zarallo-Gallardo, Jesús, Cobo-Soriano, Rosario, Lozano-Escobar, Inmaculada, Moreno-Martín, Paula, Ruiz-Moreno, Jose M., Vega-González, Rocío, García Zamora, María, Flores-Moreno, Ignacio, Valldeperas, Xavier, Broc-Iturralde, Laura, Mira, Ferran Vilaplana, Sánchez, Sandra Gómez, Figueroa, Pamela Campos, Escobar-Barranco, Jose Juan, Fernandez-Bonet, Manel, Pina-Marín, Begoña, Martínez, Eva Salinas, González Guijarro, Jacobo, Acebes García, Muxima, Sanchís, Sonia Aparicio, Fernández, Jonathan Cacelliere, Belmonte Grau, Marta, Ascaso Puyuelo, Francisco Javier, Honrubia Grijalbo, Ana, Boned Murillo, Ana, Díaz Barreda, María Dolores, Rivasés, Guillermo Pérez, El Bakkali, Ismael Bakkali, Gallego-Pinazo, Roberto, Cholbi, Marta, Dolz-Marco, Rosa, Figueroa, Marta S., Ciancas, Esther, Gonzalez-López, Julio José, Haskour, Cesar Azrak, Sánchez, Alvaro Piñero, Muñoz Sanz, Nélida, Carreño, Ester, Ventura, Nestor, Carnota-Méndez, Pablo, Méndez-Vázquez, Carlos, Torres-Borrego, Carlos, Velázquez-Villoria, Daniel, García-Layana, Alfredo, Saenz de Viteri, Manuel, Alonso, Elena, Castillón Torre, Luis J., Muñoz, Pablo Catalán, Sempere, María Eugenia Tena, Álvarez Gil, María de Fátima, Piñas García, Purificación, Mantrana Bermejo, María Eugenia, de los Mozos, Francisco Javier Lavid, Asencio Duran, Mónica, Arias-Barquet, Lluis, Cobos Martín, Estefanía, Parra, Daniel Lorenzo, Rodríguez-Núñez, Marta, Gesto, Ana Campo, Pareja Esteban, Jesús, Ruiz del Tiempo, María del Pilar, Rodríguez-Maqueda, Mariano, Espiñeira Periñan, María Angeles, and Sotomayor Toribio, Magdalena

Abstract

To evaluate the influence of macular neovascularization (MNV) lesion type on 12-month clinical outcomes in treatment-naive eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF drugs nationwide.

Published
2024
Full Text
View/download PDF

32. Prevalence of Vitreoretinal Interface Abnormalities on Spectral-Domain OCT in Healthy Participants over 45 Years of Age

Author

Donate, Juan, Fernandez Vigo, José, Figueroa, Marta S., Arriba Palomero, Pablo, Huguet, Cristina, Amorós, David, García-Layana, Alfredo, Alfonso Bartolozzi, Belén, Amat, Pedro, Lugo Quintás, Francisco, Esteban González, Eduardo, Garrido Hermosilla, Antonio, Ascaso Puyuelo, Javier, Vélez, Mireya Martínez, Gallego-Pinazo, Roberto, Andreu-Fenoll, María, Fernández Larripa, Sonia, Abecia, Emilio, Arias, Lluis, Fillol, Alejandro, López-Guajardo, Lorenzo, Rubio Álvarez, Noelia, Abraldes, Maximino, Rodíguez-Cid, María José, Giralt, Joan, Becerra Rangel, Erika Andrea, López Gálvez, Maria Isabel, Ramoa Osorio, María Rosalba, Zapata, Miguel Ángel, Garriga, Mireia, Martinez-Alday, Nerea, Fonollosa, Alex, Sararols, Laura, Gutiérrez, Laura, Ruiz-Moreno, José María, Zapata, Miguel A., and Gallego Pinazo, Roberto

Published
2017
Full Text
View/download PDF

33. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases

Author

Pierre-Henry Gabrielle, Vuong Nguyen, Louis Arnould, Francesco Viola, Javier Zarranz-Ventura, Daniel Barthelmes, Catherine Creuzot-Garcher, Mark Gillies, D. Squirrell, J. Gilhotra, C. Brooijmans, O. Tigchelaar-Besling, A. Cohn, F. Chen, A. McGeorge, S. Welch, N. Jaross, P. Peters, R. Barry, I. McLean, T. Guillaumie, A. Miri, J. Korobelnik, P. Gabrielle, M. Weber, B. Walid, S. Tick, S. Valen, A. Field, S. Wickremasinghe, C. Dayajeewa, J. Wells, R. Essex, A. Dunlop, K. Michalova, C. Ng, S. Young, G. MIMOUN, C. Generic, R. Guymer, P. Carnota, C. Torres Borrego, R. Dolz Marco, R. Gallego-Pinazo, J. Pareja Esteban, A. García Layana, M. Saenz-de-Viteri, J. Uzzan, R. Ferrier, J. Ah-Chan, L. Chow, H. Steiner, A. Amini, G. Clark, N. Wittles, P. Windle, J. Vingerling, C. Clement, M. Gillies, A. Hunt, P. Beaumont, L. Cottee, K. Lee, H. Mack, Z. Louw, J. Lusthaus, J. Chen, J. Landers, K. Billing, N. Saha, S. Lake, D. Qatarneh, R. Phillips, M. Perks, K. Banon, M. Guarro, G. Londoño, C. Rethati, L. Sararols, J. Suarez, F. Viola, S. Lan Oei, S. Fraser-Bell, R. Montejano Milner, C. Arruabarrena, E. Chong, S. Lal, A. Higueras, F. Ascaso, A. Boned Murillo, M. Díaz, G. Perez Rivases, S. Alforja Castiella, C. Bernal-Morales, R. Casaroli-Marano, M. Figueras-Roca, J. Izquierdo-Serra, A. Moll Udina, A. Parrado-Carrillo, J. Zarranz-Ventura, j. escobar, F. Lavid, M. Alvarez Gil, P. Catalán Muñoz, M. Tena Sempere, L. Cerri, F. RICCI, L. Broc Iturralde, P. Campos Figueroa, S. Gómez Sánchez, X. Valldeperas, F. Vilaplana, E. Carreño, N. Munoz Sanz, N. Ventura Abreu, M. Asencio Duran, P. Calvo, J. Sanchez, E. Almazan Alonso, I. Flores-Moreno, M. Garcia Zamora, E. Ciancas, J. Gonzalez-Lopez, M. de la Fuente, M. Rodriguez Maqueda, E. Cobos, D. Lorenzo, L. Cordoves, m. Acebes, S. Aparicio-Sanchis, A. Fernández Hortelano, J. Zarallo-Gallardo, C. Azrak, A. Piñero Sánchez, P. Almuina-Varela, L. García García, E. Salinas Martínez, M. Castilla Marti, A. Campo Gesto, M. Rodriguez Núñez, G. Furness, T. Ponsioen, G. Wilson, L. Manning, I. McAllister, Tim Isaacs, A. Invernizzi, L. Castelnovo, G. Michel, B. Wolff, J. Arnold, H. Cass, D. Chan, T. Tan, L. OToole, K. Tang, C. Chung, H. Beylerian, V. DAIEN, G. Banerjee, M. Morgan, I. Reddie, J. Ongkosuwito, F. Verbraak, R. Schlingemann, s. piermarocchi, A. Thompson, J. Game, C. Thompson, R. Chalasani, M. Chilov, A. Fung, S. Nothling, R. Chong, A. Hunyor, C. Younan, R. Barnes, D. Sharp, A. Vincent, N. Murray, S. Ah-Moye, C. Hennings, H. Mehta, P. Monaco, G. Cheung, N. Karia, D. Louis, S. Every, P. Lockie, M. van Hecke, J. van Lith-Verhoeven, J. Wong, J. Grigg, P. Hinchcliffe, D. Barthelmes, E. Diaz De Durana Santa Coloma, G. Garay-Aramburu, S. Vujosevic, H. Brosa Morros, M. Daniell, A. Harper, L. Lim, J. ODay, D. Velazquez Villoria, C. Hooper, N. Klaassen-Broekema, and R. Smit

Subjects
Ophthalmology
Published
2022
Full Text
View/download PDF

34. Evaluation of Macular Retinal Vessels and Histological Changes in Two Cases of COVID-19

Author

Maria Hernandez, Jorge González-Zamora, Sergio Recalde, Maite Moreno-Orduña, Valentina Bilbao-Malavé, Manuel Saenz de Viteri, Manuel F. Landecho, Patricia Fernandez-Robredo, and Alfredo García-Layana

Subjects
SARS-CoV-2, COVID-19, macula, retina, vasculature, ACE2, Biology (General), QH301-705.5
Abstract

The purpose of this study was to assess vascular and histological alterations in two COVID-19 and three control post-mortem retinas. The macular areas of flat-mounted samples were processed for immunofluorescence. Lectin and collagen IV positive vessels were captured under confocal microscopy, and endothelium loss and tortuosity were analyzed. Expression of ACE2 (angiotensin-converting enzyme 2) (the receptor for SARS-CoV-2), Iba1 (ionized calcium-binding adaptor molecule 1) and GFAP (glial fibrillary acidic protein) were quantified in retinal sections. The number of lectin vessels in COVID-19 retinas decreased by 27% compared to the control (p < 0.01) and the tortuosity increased in COVID-19 retinas (7.3 ± 0.2) vs. control retinas (6.8 ± 0.07) (p < 0.05). Immunofluorescence analysis revealed an increase in ACE2 (2.3 ± 1.3 vs. 1.0 ± 0.1; p < 0.0001) and Iba1 expression (3.06 ± 0.6 vs. 1.0 ± 0.1; p < 0.01) in COVID-19 sections whereas no changes in GFAP were observed. Analysis of the COVID-19 macular retinal tissue suggested that endothelial cells are a preferential target of SARS-CoV-2 with subsequent changes through their ACE2 receptor expression and morphology. Thus, microglial activation was hyperactive when facing an ensuing immunological challenge after SARS-CoV-2 infection.

Published
2021
Full Text
View/download PDF

35. Early and intermediate age-related macular degeneration: update and clinical review

Author

García-Layana A, Cabrera-López F, García-Arumí J, Arias-Barquet L, and Ruiz-Moreno JM

Subjects
Age-related macular degeneration, early AMD, intermediate AMD, risk factors, classification, prevention, nutritional supplementation., Geriatrics, RC952-954.6
Abstract

Alfredo García-Layana,1–3 Francisco Cabrera-López,4,5 José García-Arumí,6–8 Lluís Arias-Barquet,9,10 José M Ruiz-Moreno3,11,12 1Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain; 2Sociedad Española de Retina y Vítreo (SERV), Madrid, Spain; 3Red Telemática de Investigación Cooperativa Oftared, Instituto de Salud Carlos III, Madrid, Spain; 4Service of Ophthalmology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain; 5Las Palmas Gran Canaria University, Las Palmas de Gran Canaria, Spain; 6Department of Retina and Vitreous, Instituto de Microcirugía Ocular (IMO), Barcelona, Spain; 7Department of Ophthalmology, Universidad Autónoma de Barcelona, Barcelona, Spain; 8Hospital Universitario Valle Hebrón, Barcelona, Spain; 9Section of Medical-Surgical Retina, Service of Ophthalmology, Hospital Universitari de Bellvitge, Barcelona, Spain; 10University of Barcelona, Barcelona, Spain; 11Universidad Castilla-La Mancha, Albacete, Spain; 12Vissum Corporación Oftalmológica, Madrid, Spain Abstract: Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in developed countries. With the aging of population, AMD will become globally an increasingly important and prevalent disease worldwide. It is a complex disease whose etiology is associated with both genetic and environmental risk factors. An extensive decline in the quality of life and progressive need of daily living assistance resulting from AMD among those most severely affected highlights the essential role of preventive strategies, particularly advising patients to quit smoking. In addition, maintaining a healthy diet, controlling other risk factors (such as hypertension, obesity, and atherosclerosis), and the use of nutritional supplements (antioxidants) are recommendable. Genetic testing may be especially important in patients with a family history of AMD. Recently, unifying criteria for the clinical classification of AMD, defining no apparent aging changes; normal aging changes; and early, intermediate, and late AMD stages, are of value in predicting AMD risk of progression and in establishing recommendations for the diagnosis, therapeutic approach, and follow-up of patients. The present review is focused on early and intermediate AMD and presents a description of the clinical characteristics and ophthalmological findings for these stages, together with algorithms for the diagnosis and management of patients, which are easily applicable in daily clinical practice. Keywords: age-related macular degeneration, early AMD, intermediate AMD, risk factors, classification, prevention, nutritional supplementation

Published
2017

37. Recommendations for ophthalmologic practice during the easing of COVID‐19 control measures

Author

Gegúndez Fernández, José Antonio, Llovet Osuna, Fernando, Fernández Vigo, José Ignacio, Mendicute del Barrio, Javier, Pablo Júlvez, Luis, Muñoz Negrete, Francisco José, Zarranz Ventura, Javier, Durán de la Colina, Juan, Rojas Silva, Victoria, de, Jiménez Alfaro, Íñigo, Calonge Cano, Margarita, Galindo Ferreiro, Alicia, Castillo Gómez, Alfredo, Mantolán Sarmiento, Cristina, Duch Samper, Antonio, Álvarez de Toledo-Elizalde, Juan, Duch Mestres, Francesc, Elies Amat, Daniel, Ortega Usobiaga, Julio, Saornil Álvarez, María Antonia, Villarrubia Cuadrado, Alberto, Garay Aramburu, Gonzaga, Fonollosa Carduch, Alejandro, Cordero Coma, Miguel, García Delpech, Salvador, Cárceles Cárceles, Juan Antonio, Benítez del Castillo, José Manuel, Gómez De Liaño Sánchez, Pilar, Harto Castaño, Miguel, Arias Puente, Alfonso, García Layana, Alfredo, Sociedades Oftalmológicas Españolas, Gegúndez Fernández, José Antonio, Llovet Osuna, Fernando, Fernández Vigo, José Ignacio, Mendicute del Barrio, Javier, Pablo Júlvez, Luis, Muñoz Negrete, Francisco José, Zarranz Ventura, Javier, Durán de la Colina, Juan, Rojas Silva, Victoria, de, Jiménez Alfaro, Íñigo, Calonge Cano, Margarita, Galindo Ferreiro, Alicia, Castillo Gómez, Alfredo, Mantolán Sarmiento, Cristina, Duch Samper, Antonio, Álvarez de Toledo-Elizalde, Juan, Duch Mestres, Francesc, Elies Amat, Daniel, Ortega Usobiaga, Julio, Saornil Álvarez, María Antonia, Villarrubia Cuadrado, Alberto, Garay Aramburu, Gonzaga, Fonollosa Carduch, Alejandro, Cordero Coma, Miguel, García Delpech, Salvador, Cárceles Cárceles, Juan Antonio, Benítez del Castillo, José Manuel, Gómez De Liaño Sánchez, Pilar, Harto Castaño, Miguel, Arias Puente, Alfonso, García Layana, Alfredo, and Sociedades Oftalmológicas Españolas

Abstract

Acceso libre en la web del editor, In the context of the COVID‐19 pandemic, this paper provides recommendations for medical eye care during the easing of control measures after lockdown. The guidelines presented are based on a literature review and consensus among all Spanish Ophthalmology Societies regarding protection measures recommended for the ophthalmologic care of patients with or without confirmed COVID‐19 in outpatient, inpatient, emergency and surgery settings. We recommend that all measures be adapted to the circumstances and availability of personal protective equipment at each centre and also highlight the need to periodically update recommendations as we may need to readopt more restrictive measures depending on the local epidemiology of the virus. These guidelines are designed to avoid the transmission of SARS‐CoV‐2 among both patients and healthcare staff as we gradually return to normal medical practice, to prevent postoperative complications and try to reduce possible deficiencies in the diagnosis, treatment and follow‐up of the ophthalmic diseases. With this update (5th) the Spanish Society of Ophthalmology is placed as one of the major ophthalmology societies providing periodic and systematized recommendations for ophthalmic care during the COVID‐19 pandemic., Unidad Docente de Inmunología, Oftalmología y ORL, Fac. de Óptica y Optometría, TRUE, pub

Published
2023

38. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.

Author

Pablo Plaza-Ramos, Enrique Borque, and Alfredo García-Layana

Subjects
Medicine, Science
Abstract

PURPOSE:To evaluate the efficacy and safety of ranibizumab and aflibercept in the treatment of diabetic macular edema in a real world study, and to compare the two treatments with each other. METHODS:Retrospective observational study of 213 eyes from 141 patients with diabetic macular edema was completed between June 2014 and June 2016. 122 were treated with ranibizumab intravitreal injection and 91 with aflibercept intravitreal injection, with a loading phase of 3 injections and a Pro Re Nata protocol. The drug was selected by the physician and fluorescein angiography was performed by physician`s criteria. Re-treatment was performed when a decline in BCVA, an increase of central macular thickness or an increase or persistence of intraretinal fluid in OCT was observed. The primary outcome was the mean change in best corrected visual acuity at 1 year, while central macular thickness, central macular volume, the number of injections and visits were evaluated as secondary outcomes. The correlation between BCVA at 4th month visit and BCVA at 12th month visit was also evaluated. RESULTS:The mean baseline best corrected visual acuity for the eyes treated with ranibizumab was 0.55 (+/- 0.35) logMAR, and with aflibercept it was 0.48 (+/- 0.29) (P = 0.109). Best corrected visual acuity improved in both groups, and at the end of the follow-up was 0.40 (+/- 0.35) in the ranibizumab group and 0.40 (+/- 0.29) in the aflibercept group (P = 0.864). Best corrected visual acuity at 4th month visit is correlated at a high value (R = 0.789) with the one at the end of the study. No differences were found in central macular thickness, central macular volume and glycosylated hemoglobin when adjusting with baseline values. The overall number of injections was 5.77 (+/- 2.01), being 5.56 (+/- 2.0) in the ranibizumab group and 6.07 (+/- 1.99) in the aflibercept group (P = 0.069). The main outcome determining final best corrected visual acuity was the baseline best corrected visual acuity (P

Published
2019
Full Text
View/download PDF

40. Persistent Retinal Microvascular Impairment in COVID-19 Bilateral Pneumonia at 6-Months Follow-Up Assessed by Optical Coherence Tomography Angiography

Author

Valentina Bilbao-Malavé, Jorge González-Zamora, Manuel Saenz de Viteri, Miriam de la Puente, Elsa Gándara, Anna Casablanca-Piñera, Claudia Boquera-Ventosa, Javier Zarranz-Ventura, Manuel F. Landecho, and Alfredo García-Layana

Subjects
SARS-COV-2, COVID-19, coronavirus, retina, microvascular, cotton wool spots, Biology (General), QH301-705.5
Abstract

The purpose of this study was to evaluate the long-term evolution of retinal changes in COVID-19 patients with bilateral pneumonia. A total of 17 COVID-19 patients underwent retinal imaging 6 months after hospital discharge with structural optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). The parafoveal retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) were significantly thinner in COVID-19 patients at 6 months compared to 0 months (p = p = 0.006) but persisted significantly thickened, compared to controls (p = 0.02). The vascular density (VD) at 6 months persisted significantly decreased when compared to the control group, and no significant differences were found with the 0 months evaluation; in addition, when analyzed separately, women showed a worsening in the VD. Moreover, a significantly greater foveal area zone (FAZ) (p = 0.003) was observed in COVID-19 patients at 6 months, compared to 0 months. The cotton wool spots (CWSs) observed at baseline were no longer present at 6 months, except for one patient that developed new ones. This study demonstrates that some of the previously known microvascular alterations resulting from COVID-19, persist over time and are still evident 6 months after hospital discharge in patients who have suffered from bilateral pneumonia.

Published
2021
Full Text
View/download PDF

41. Retinal Microvascular Impairment in COVID-19 Bilateral Pneumonia Assessed by Optical Coherence Tomography Angiography

Author

Jorge González-Zamora, Valentina Bilbao-Malavé, Elsa Gándara, Anna Casablanca-Piñera, Claudia Boquera-Ventosa, Manuel F. Landecho, Javier Zarranz-Ventura, and Alfredo García-Layana

Subjects
SARS-COV-2, COVID-19, coronavirus, retina, microvascular, cotton wool spot, Biology (General), QH301-705.5
Abstract

The purpose of this study was to evaluate the presence of retinal and microvascular alterations in COVID-19 patients with bilateral pneumonia due to SARS-COV-2 that required hospital admission and compare this with a cohort of age- and sex-matched controls. COVID-19 bilateral pneumonia patients underwent retinal imaging 14 days after hospital discharge with structural optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) measurements. Vessel density (VD) and foveal avascular zone (FAZ) area were evaluated in the superficial, deep capillary plexus (SCP, DCP), and choriocapillaris (CC). After exclusion criteria, only one eye per patient was selected, and 50 eyes (25 patients and 25 controls) were included in the analysis. COVID-19 patients presented significantly thinner ganglion cell layer (GCL) (p = 0.003) and thicker retinal nerve fiber layer (RNFL) compared to controls (p = 0.048), and this RNFL thickening was greater in COVID-19 cases with cotton wool spots (CWS), when compared with patients without CWS (p = 0.032). In both SCP and DCP, COVID-19 patients presented lower VD in the foveal region (p < 0.001) and a greater FAZ area than controls (p = 0.007). These findings suggest that thrombotic and inflammatory phenomena could be happening in the retina of COVID-19 patients. Further research is warranted to analyze the longitudinal evolution of these changes over time as well as their correlation with disease severity.

Published
2021
Full Text
View/download PDF

42. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

Author

de Andrés-Nogales, Fernando, Casado, Miguel Ángel, Trillo, José Luis, Ruiz-Moreno, José María, Martínez-Sesmero, José Manuel, Peralta, Gemma, Poveda, José Luis, Ortiz, Pere, Ignacio, Emilio, Zarranz-Ventura, Javier, Udaondo, Patricia, Mur, Carlos, Álvarez, Eloísa, Cervera, Enrique, Martínez, Mercedes, Llorente, Iñaki, Zulueta, Jacinto, Rodríguez-Maqueda, Mariano, García-Layana, Alfredo, and Martínez-Olmos, José

Abstract

Background: The clinical and economic management of retinal diseases has become more complex following the introduction of new intravitreal treatments. Multicriteria decision analysis (MCDA) offers the potential to overcome the challenges associated with traditional decision-making tools. Objectives: A MCDA to determine the most relevant criteria to decision-making in the management of diabetic macular edema (DME) based on the perspectives of multiple stakeholders in Spain was developed. This MCDA was termed the MULTIDEX-EMD study. Methods: Nineteen stakeholders (7 physicians, 4 pharmacists, 5 health authorities and health management experts, 1 psychologist, and 2 patient representatives) participated in this three-phase project. In phase A, an advisory board defined all of the criteria that could influence DME treatment decision-making. These criteria were then screened using a discrete choice experiment (DCE) (phase B). Next, a multinomial logit model was fitted by applying the backward elimination algorithm (relevant criteria: pvalue &lt; 0.05). Finally, the results were discussed in a deliberative process (phase C). Results: Thirty-one criteria were initially defined (phase A) and grouped into 5 categories: efficacy/effectiveness, safety, organizational and economic impact, patient-reported outcomes, and other therapeutic features. The DCE results (phase B) showed that 10 criteria were relevant to the decision-making process for a 50- to 65-year-old DME patient: mean change in best corrected visual acuity (pvalue &lt; 0.001), percentage of patients with an improvement of ≥ 15 letters (pvalue &lt; 0.001), effect duration per administration (pvalue = 0.008), retinal detachment (pvalue &lt; 0.001), endophthalmitis (pvalue = 0.012), myocardial infarction (pvalue &lt; 0.001), intravitreal hemorrhage (pvalue = 0.021), annual treatment cost per patient (pvalue = 0.001), health-related quality of life (HRQoL) (pvalue = 0.004), and disability level (pvalue = 0.021). Conclusions: From a multi-stakeholder perspective, the selection of an appropriate treatment for DME patients should guarantee patient safety and maximize the visual acuity improvement and treatment effect duration. It should also contribute to system sustainability by being affordable, it should have a positive impact on HRQoL, and it should prevent disability.

Published
2024
Full Text
View/download PDF

44. Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study

Author

Audrey Giocanti-Aurégan, Alfredo García-Layana, Tunde Peto, Brittany Gentile, Gloria C Chi, Mirela Mirt, Charlotte E Kosmas, Jeremy Lambert, Sally Lanar, Hannah B Lewis, and Nancy M Holekamp

Subjects
genetic structures, SDG 3 - Good Health and Well-being, Patient Preference and Adherence, Health Policy, Medicine (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), eye diseases, Social Sciences (miscellaneous)
Abstract

Audrey Giocanti-Aurégan,1 Alfredo García-Layana,2 Tunde Peto,3 Brittany Gentile,4 Gloria C Chi,4 Mirela Mirt,5 Charlotte E Kosmas,6 Jeremy Lambert,7 Sally Lanar,7 Hannah B Lewis,6 Nancy M Holekamp8 1Ophthalmology Department, Avicenne Hospital, Bobigny, France; 2Clínica Universidad de Navarra, University of Navarra, Pamplona, 31009, Spain; 3Queen’s University Belfast, Belfast, UK; 4Genentech, South San Francisco, CA, USA; 5F. Hoffmann-La Roche, Basel, Switzerland; 6Patient Centred Outcomes, ICON Plc, Reading, UK; 7Patient Centred Outcomes, ICON Plc, Lyon, France; 8Pepose Vision Institute, Chesterfield, MO, USACorrespondence: Audrey Giocanti-Aurégan, Ophthalmology Department, Avicenne hospital, 125 Rue de Stalingrad, Bobigny Cedex, 93009, France, Tel +33 14 895 5815, Fax +33 14 895 5212, Email audrey.giocanti@aphp.frPurpose: Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) patients treated with intravitreally injected anti-vascular endothelial growth factor (anti-VEGF) monotherapies achieve lower vision improvements compared with patients in clinical trials. This qualitative research study aimed to better understand the real-world anti-VEGF treatment experience from nAMD and DME patients’, caregivers’, and retina specialists’ perspectives.Methods: One-time, semi-structured, individual interviews were conducted with adult patients with nAMD or DME treated with anti-VEGF injections for ≥ 12 months, their caregivers, and experienced retina specialists. Interview transcripts were analyzed qualitatively using a thematic analysis approach.Results: A total of 49 nAMD and 46 DME patients, 47 nAMD and 33 DME caregivers, and 62 retina specialists were interviewed in the USA, Canada, France, Germany, Italy and Spain. Most (79%) patients and caregivers reported disruptions to their routine on the day before, the day of, or the day after anti-VEGF injection. Seven nAMD patients (14%) and 14 DME patients (30%) reported having missed an injection visit. The most frequently reported driver for adherence for patients was the doctor–patient relationship (n=66, 70%), whereas for caregivers, it was the ease of booking an appointment (n=25, 32%). Retina specialists reported patient education on the treatment (n=28, 45%) as the most important driver. Treatment barriers could be grouped into four categories: tolerability, clinical factors, logistical parameters and human factors. The most frequently reported barrier to adherence for patients and caregivers was related to side effects (pain/discomfort/irritation: n=63, 67% of patients; n=52, 66% of caregivers), whereas for retina specialists it was logistical parameters (travel logistics: n=44, 71%).Conclusion: This study highlights the importance of the doctor–patient relationship and patient education as key drivers, and treatment tolerability and logistics as key barriers to treatment adherence. Improved doctor–patient relationship/communication and patient education together with new therapies offering convenience, long-acting effectiveness, and better tolerability may improve treatment adherence.Keywords: qualitative interviews, treatment experience, adherence, neovascular age-related macular degeneration, diabetic macular edema

Published
2022
Full Text
View/download PDF

47. The relationship between outdoor exposure and myopia on university students, measured by conjunctival ultraviolet autofluorescence ( <scp>CUVAF</scp> )

Author

Sergio Recalde, Valentina Bilbao, Maria Hernandez, Jorge Gonzalez‐Zamora, Miriam De la Puente, Elena Escriche, Pablo Ruiz, Jaione Bezunartea, Ainara Mariezkurrena, Elena Alonso, Manuel Saenz de Viteri, Jesús Barrio, Alfredo García Layana, and Patricia Fernandez‐Robredo

Subjects
Ophthalmology, General Medicine
Published
2022
Full Text
View/download PDF

49. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases

Author

Gabrielle, Pierre-Henry, primary, Nguyen, Vuong, additional, Arnould, Louis, additional, Viola, Francesco, additional, Zarranz-Ventura, Javier, additional, Barthelmes, Daniel, additional, Creuzot-Garcher, Catherine, additional, Gillies, Mark, additional, Squirrell, D., additional, Gilhotra, J., additional, Brooijmans, C., additional, Tigchelaar-Besling, O., additional, Cohn, A., additional, Chen, F., additional, McGeorge, A., additional, Welch, S., additional, Jaross, N., additional, Peters, P., additional, Barry, R., additional, McLean, I., additional, Guillaumie, T., additional, Miri, A., additional, Korobelnik, J., additional, Gabrielle, P., additional, Weber, M., additional, Walid, B., additional, Tick, S., additional, Valen, S., additional, Field, A., additional, Wickremasinghe, S., additional, Dayajeewa, C., additional, Wells, J., additional, Essex, R., additional, Dunlop, A., additional, Michalova, K., additional, Ng, C., additional, Young, S., additional, MIMOUN, G., additional, Generic, C., additional, Guymer, R., additional, Carnota, P., additional, Torres Borrego, C., additional, Dolz Marco, R., additional, Gallego-Pinazo, R., additional, Pareja Esteban, J., additional, García Layana, A., additional, Saenz-de-Viteri, M., additional, Uzzan, J., additional, Ferrier, R., additional, Ah-Chan, J., additional, Chow, L., additional, Steiner, H., additional, Amini, A., additional, Clark, G., additional, Wittles, N., additional, Windle, P., additional, Vingerling, J., additional, Clement, C., additional, Gillies, M., additional, Hunt, A., additional, Beaumont, P., additional, Cottee, L., additional, Lee, K., additional, Mack, H., additional, Louw, Z., additional, Lusthaus, J., additional, Chen, J., additional, Landers, J., additional, Billing, K., additional, Saha, N., additional, Lake, S., additional, Qatarneh, D., additional, Phillips, R., additional, Perks, M., additional, Banon, K., additional, Guarro, M., additional, Londoño, G., additional, Rethati, C., additional, Sararols, L., additional, Suarez, J., additional, Viola, F., additional, Lan Oei, S., additional, Fraser-Bell, S., additional, Montejano Milner, R., additional, Arruabarrena, C., additional, Chong, E., additional, Lal, S., additional, Higueras, A., additional, Ascaso, F., additional, Boned Murillo, A., additional, Díaz, M., additional, Perez Rivases, G., additional, Alforja Castiella, S., additional, Bernal-Morales, C., additional, Casaroli-Marano, R., additional, Figueras-Roca, M., additional, Izquierdo-Serra, J., additional, Moll Udina, A., additional, Parrado-Carrillo, A., additional, Zarranz-Ventura, J., additional, escobar, j., additional, Lavid, F., additional, Alvarez Gil, M., additional, Catalán Muñoz, P., additional, Tena Sempere, M., additional, Cerri, L., additional, RICCI, F., additional, Broc Iturralde, L., additional, Campos Figueroa, P., additional, Gómez Sánchez, S., additional, Valldeperas, X., additional, Vilaplana, F., additional, Carreño, E., additional, Munoz Sanz, N., additional, Ventura Abreu, N., additional, Asencio Duran, M., additional, Calvo, P., additional, Sanchez, J., additional, Almazan Alonso, E., additional, Flores-Moreno, I., additional, Garcia Zamora, M., additional, Ciancas, E., additional, Gonzalez-Lopez, J., additional, de la Fuente, M., additional, Rodriguez Maqueda, M., additional, Cobos, E., additional, Lorenzo, D., additional, Cordoves, L., additional, Acebes, m., additional, Aparicio-Sanchis, S., additional, Fernández Hortelano, A., additional, Zarallo-Gallardo, J., additional, Azrak, C., additional, Piñero Sánchez, A., additional, Almuina-Varela, P., additional, García García, L., additional, Salinas Martínez, E., additional, Castilla Marti, M., additional, Campo Gesto, A., additional, Rodriguez Núñez, M., additional, Furness, G., additional, Ponsioen, T., additional, Wilson, G., additional, Manning, L., additional, McAllister, I., additional, Isaacs, Tim, additional, Invernizzi, A., additional, Castelnovo, L., additional, Michel, G., additional, Wolff, B., additional, Arnold, J., additional, Cass, H., additional, Chan, D., additional, Tan, T., additional, OToole, L., additional, Tang, K., additional, Chung, C., additional, Beylerian, H., additional, DAIEN, V., additional, Banerjee, G., additional, Morgan, M., additional, Reddie, I., additional, Ongkosuwito, J., additional, Verbraak, F., additional, Schlingemann, R., additional, piermarocchi, s., additional, Thompson, A., additional, Game, J., additional, Thompson, C., additional, Chalasani, R., additional, Chilov, M., additional, Fung, A., additional, Nothling, S., additional, Chong, R., additional, Hunyor, A., additional, Younan, C., additional, Barnes, R., additional, Sharp, D., additional, Vincent, A., additional, Murray, N., additional, Ah-Moye, S., additional, Hennings, C., additional, Mehta, H., additional, Monaco, P., additional, Cheung, G., additional, Karia, N., additional, Louis, D., additional, Every, S., additional, Lockie, P., additional, van Hecke, M., additional, van Lith-Verhoeven, J., additional, Wong, J., additional, Grigg, J., additional, Hinchcliffe, P., additional, Barthelmes, D., additional, Diaz De Durana Santa Coloma, E., additional, Garay-Aramburu, G., additional, Vujosevic, S., additional, Brosa Morros, H., additional, Daniell, M., additional, Harper, A., additional, Lim, L., additional, ODay, J., additional, Velazquez Villoria, D., additional, Hooper, C., additional, Klaassen-Broekema, N., additional, and Smit, R., additional

Published
2022
Full Text
View/download PDF

50. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age‐related macular degeneration

Author

Cobos, Estefania, Recalde, Sergio, Anter, Jaouad, Hernandez‐Sanchez, Maria, Barreales, Carla, Olavarrieta, Leticia, Valverde, Alicia, Suarez‐Figueroa, Marta, Cruz, Fernando, Abraldes, Maximino, Pérez‐Pérez, Julian, Fernández‐Robredo, Patricia, Arias, Luis, and García‐Layana, Alfredo

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results